|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
[peoniflorin co-treated with benzoylpaeoniflorin co-treated with Amygdalin] inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS1 mRNA]; Amygdalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS1 mRNA] |
CTD |
PMID:33149750 |
|
NCBI chr 9:122,370,533...122,395,703
Ensembl chr 9:122,370,530...122,395,703
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[peoniflorin co-treated with benzoylpaeoniflorin co-treated with Amygdalin] inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Amygdalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:33149750 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
|
G |
DNMT1 |
DNA methyltransferase 1 |
decreases activity |
EXP |
lac dye results in decreased activity of DNMT1 protein |
CTD |
PMID:23839987 |
|
NCBI chr19:10,133,346...10,194,953
Ensembl chr19:10,133,342...10,231,286
|
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
decreases expression |
EXP |
acteoside results in decreased expression of ACTA2 protein |
CTD |
PMID:33522686 |
|
NCBI chr10:88,935,074...88,991,397
Ensembl chr10:88,935,074...88,991,339
|
|
G |
AGER |
advanced glycosylation end-product specific receptor |
decreases expression |
EXP |
acteoside results in decreased expression of AGER protein |
CTD |
PMID:33522686 |
|
NCBI chr 6:32,180,969...32,184,253
Ensembl chr 6:32,180,968...32,184,322
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions decreases localization |
EXP |
acteoside promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased localization of AHR protein] acteoside results in decreased localization of AHR protein |
CTD |
PMID:21756928 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
ARNT |
aryl hydrocarbon receptor nuclear translocator |
increases localization |
EXP |
acteoside results in increased localization of ARNT protein |
CTD |
PMID:21756928 |
|
NCBI chr 1:150,809,713...150,876,599
Ensembl chr 1:150,809,713...150,876,708
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
decreases secretion multiple interactions decreases expression |
EXP |
acteoside results in decreased secretion of CCL2 protein acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA] acteoside results in decreased expression of CCL2 mRNA |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
|
|
G |
CCND1 |
cyclin D1 |
decreases expression |
EXP |
acteoside results in decreased expression of CCND1 protein |
CTD |
PMID:17634406 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCND2 |
cyclin D2 |
decreases expression |
EXP |
acteoside results in decreased expression of CCND2 protein |
CTD |
PMID:17634406 |
|
NCBI chr12:4,273,762...4,305,353
Ensembl chr12:4,269,771...4,305,353
|
|
G |
CCND3 |
cyclin D3 |
decreases expression |
EXP |
acteoside results in decreased expression of CCND3 protein |
CTD |
PMID:17634406 |
|
NCBI chr 6:41,934,933...42,048,894
Ensembl chr 6:41,934,934...42,050,357
|
|
G |
CCNE1 |
cyclin E1 |
decreases expression |
EXP |
acteoside results in decreased expression of CCNE1 protein |
CTD |
PMID:17634406 |
|
NCBI chr19:29,811,991...29,824,312
Ensembl chr19:29,811,991...29,824,312
|
|
G |
CDH1 |
cadherin 1 |
increases expression |
EXP |
acteoside results in increased expression of CDH1 protein |
CTD |
PMID:33522686 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
CDK2 |
cyclin dependent kinase 2 |
multiple interactions |
EXP |
acteoside results in decreased expression of and results in decreased activity of CDK2 protein |
CTD |
PMID:17634406 |
|
NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789
|
|
G |
CDK4 |
cyclin dependent kinase 4 |
decreases activity multiple interactions |
EXP |
acteoside results in decreased activity of CDK4 protein acteoside promotes the reaction [CDKN1A protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK4 protein] |
CTD |
PMID:17634406 |
|
NCBI chr12:57,747,727...57,752,310
Ensembl chr12:57,747,727...57,756,013
|
|
G |
CDK6 |
cyclin dependent kinase 6 |
multiple interactions |
EXP |
acteoside promotes the reaction [CDKN1A protein binds to CDK6 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK6 protein]; acteoside results in decreased expression of and results in decreased activity of CDK6 protein |
CTD |
PMID:17634406 |
|
NCBI chr 7:92,604,921...92,836,573
Ensembl chr 7:92,604,921...92,836,573
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression multiple interactions |
EXP |
acteoside results in increased expression of CDKN1A mRNA; acteoside results in increased expression of CDKN1A protein acteoside promotes the reaction [CDKN1A protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1A protein binds to CDK6 protein] |
CTD |
PMID:17634406 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
|
|
G |
CDKN1B |
cyclin dependent kinase inhibitor 1B |
increases expression multiple interactions |
EXP |
acteoside results in increased expression of CDKN1B mRNA; acteoside results in increased expression of CDKN1B protein acteoside promotes the reaction [CDKN1B protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK6 protein] |
CTD |
PMID:17634406 |
|
NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369
|
|
G |
CXCL10 |
C-X-C motif chemokine ligand 10 |
decreases secretion decreases expression multiple interactions |
EXP |
acteoside results in decreased secretion of CXCL10 protein acteoside results in decreased expression of CXCL10 mRNA acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein]; acteoside promotes the reaction [leptomycin B results in decreased secretion of CXCL10 protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
decreases expression decreases secretion multiple interactions |
EXP |
acteoside results in decreased expression of CXCL8 mRNA acteoside results in decreased secretion of CXCL8 protein [acteoside co-treated with TGFA protein] results in increased expression of CXCL8 mRNA; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein]; acteoside inhibits the reaction [leptomycin B results in increased secretion of CXCL8 protein]; acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CXCL8 mRNA] |
CTD |
PMID:21371465 PMID:21756928 PMID:21967610 PMID:23527233 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
increases expression |
EXP |
acteoside results in increased expression of CYP1A1 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions |
ISO |
acteoside inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased activity of CYP2E1 protein] |
CTD |
PMID:14672760 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
E2F1 |
E2F transcription factor 1 |
multiple interactions |
EXP |
[acteoside results in decreased phosphorylation of RB1 protein] promotes the reaction [RB1 protein binds to E2F1 protein] |
CTD |
PMID:17634406 |
|
NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions decreases phosphorylation |
EXP |
acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein modified form]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein] acteoside results in decreased phosphorylation of EGFR protein |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
HMGB1 |
high mobility group box 1 |
decreases expression |
EXP |
acteoside results in decreased expression of HMGB1 protein |
CTD |
PMID:33522686 |
|
NCBI chr13:30,456,704...30,617,597
Ensembl chr13:30,456,704...30,617,597
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
decreases expression |
EXP |
acteoside results in decreased expression of ICAM1 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
IFNG |
interferon gamma |
decreases expression multiple interactions |
EXP |
acteoside results in decreased expression of IFNG mRNA acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] |
CTD |
PMID:21371465 PMID:21756928 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IL6 |
interleukin 6 |
decreases expression multiple interactions |
EXP |
acteoside results in decreased expression of IL6 mRNA acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA] |
CTD |
PMID:21756928 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
ITGB2 |
integrin subunit beta 2 |
multiple interactions |
EXP |
acteoside inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]; acteoside inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ITGB2 protein] |
CTD |
PMID:16393473 |
|
NCBI chr21:44,885,953...44,928,815
Ensembl chr21:44,885,953...44,931,989
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
EXP |
acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein] acteoside results in decreased phosphorylation of MAPK1 protein acteoside results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
decreases phosphorylation multiple interactions increases phosphorylation |
EXP |
acteoside results in decreased phosphorylation of MAPK3 protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein] acteoside results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
NOX1 |
NADPH oxidase 1 |
decreases activity |
EXP |
acteoside results in decreased activity of NOX1 protein |
CTD |
PMID:16393473 |
|
NCBI chr X:100,843,324...100,874,359
Ensembl chr X:100,843,324...100,874,359
|
|
G |
PTGDS |
prostaglandin D2 synthase |
affects binding |
EXP |
acteoside binds to PTGDS protein |
CTD |
PMID:26456343 |
|
NCBI chr 9:136,977,504...136,981,742
Ensembl chr 9:136,975,092...136,981,742
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[acteoside co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of PTGS2 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
RB1 |
RB transcriptional corepressor 1 |
decreases phosphorylation multiple interactions |
EXP |
acteoside results in decreased phosphorylation of RB1 protein [acteoside results in decreased phosphorylation of RB1 protein] promotes the reaction [RB1 protein binds to E2F1 protein] |
CTD |
PMID:17634406 |
|
NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases phosphorylation increases phosphorylation |
EXP |
acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein] acteoside results in decreased phosphorylation of RELA protein acteoside results in increased phosphorylation of RELA protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr11:65,653,601...65,662,916
Ensembl chr11:65,653,599...65,663,090
|
|
G |
SMAD2 |
SMAD family member 2 |
increases phosphorylation |
EXP |
acteoside results in increased phosphorylation of SMAD2 protein |
CTD |
PMID:17634406 |
|
NCBI chr18:47,808,957...47,930,872
Ensembl chr18:47,808,957...47,931,146
|
|
G |
SMAD3 |
SMAD family member 3 |
increases phosphorylation |
EXP |
acteoside results in increased phosphorylation of SMAD3 protein |
CTD |
PMID:17634406 |
|
NCBI chr15:67,065,602...67,195,169
Ensembl chr15:67,063,763...67,195,173
|
|
G |
SMAD7 |
SMAD family member 7 |
increases expression |
EXP |
acteoside results in increased expression of SMAD7 protein |
CTD |
PMID:33522686 |
|
NCBI chr18:48,919,853...48,950,965
Ensembl chr18:48,919,853...48,950,965
|
|
G |
SNAI1 |
snail family transcriptional repressor 1 |
decreases expression |
EXP |
acteoside results in decreased expression of SNAI1 protein |
CTD |
PMID:33522686 |
|
NCBI chr20:49,982,980...49,988,886
Ensembl chr20:49,982,980...49,988,886
|
|
G |
SNAI2 |
snail family transcriptional repressor 2 |
decreases expression |
EXP |
acteoside results in decreased expression of SNAI2 protein |
CTD |
PMID:33522686 |
|
NCBI chr 8:48,917,598...48,921,429
Ensembl chr 8:48,917,598...48,921,740
|
|
G |
SOD2 |
superoxide dismutase 2 |
decreases expression |
EXP |
acteoside results in decreased expression of SOD2 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
TGFA |
transforming growth factor alpha |
multiple interactions |
EXP |
[acteoside co-treated with TGFA protein] results in increased expression of CXCL8 mRNA; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein modified form]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr 2:70,447,284...70,553,826
Ensembl chr 2:70,447,284...70,554,193
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
increases expression |
EXP |
acteoside results in increased expression of TGFB1 mRNA |
CTD |
PMID:17634406 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TGFBR1 |
transforming growth factor beta receptor 1 |
decreases expression |
EXP |
acteoside results in decreased expression of TGFBR1 protein |
CTD |
PMID:33522686 |
|
NCBI chr 9:99,104,038...99,154,192
Ensembl chr 9:99,104,038...99,154,192
|
|
G |
TGFBR2 |
transforming growth factor beta receptor 2 |
decreases expression |
EXP |
acteoside results in decreased expression of TGFBR2 protein |
CTD |
PMID:33522686 |
|
NCBI chr 3:30,606,356...30,694,142
Ensembl chr 3:30,606,601...30,694,142
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] |
CTD |
PMID:21756928 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
decreases expression |
EXP |
acteoside results in decreased expression of VCAM1 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045
|
|
|
G |
ITPR2 |
inositol 1,4,5-trisphosphate receptor type 2 |
multiple interactions increases activity |
ISO |
2-aminoethoxydiphenyl borate inhibits the reaction [[adenophostin A results in increased activity of ITPR2 protein] which results in increased transport of Calcium]; [adenophostin A results in increased activity of ITPR2 protein] which results in increased transport of Calcium; xestospongin C inhibits the reaction [[adenophostin A results in increased activity of ITPR2 protein] which results in increased transport of Calcium] |
CTD |
PMID:15201137 |
|
NCBI chr12:26,335,352...26,833,194
Ensembl chr12:26,335,352...26,833,194
|
|
G |
ITPR3 |
inositol 1,4,5-trisphosphate receptor type 3 |
multiple interactions |
ISO |
adenophostin A analog binds to and results in increased activity of ITPR3 protein; adenophostin A binds to and results in increased activity of ITPR3 protein |
CTD |
PMID:18247493 |
|
NCBI chr 6:33,621,322...33,696,562
Ensembl chr 6:33,620,365...33,696,574
|
|
|
G |
ATG10 |
autophagy related 10 |
increases expression |
ISO |
Trehalose results in increased expression of ATG10 mRNA |
CTD |
PMID:30335591 |
|
NCBI chr 5:81,972,023...82,256,133
Ensembl chr 5:81,972,023...82,276,857
|
|
G |
ATG12 |
autophagy related 12 |
increases expression |
ISO |
Trehalose results in increased expression of ATG12 mRNA |
CTD |
PMID:30335591 |
|
NCBI chr 5:115,828,200...115,841,565
Ensembl chr 5:115,828,200...115,841,837
|
|
G |
ATG5 |
autophagy related 5 |
increases expression |
ISO |
Trehalose results in increased expression of ATG5 mRNA |
CTD |
PMID:23851366 |
|
NCBI chr 6:106,184,476...106,325,760
Ensembl chr 6:106,045,423...106,325,791
|
|
G |
BAG3 |
BAG cochaperone 3 |
increases expression |
ISO |
Trehalose results in increased expression of BAG3 mRNA |
CTD |
PMID:30335591 |
|
NCBI chr10:119,651,380...119,677,819
Ensembl chr10:119,651,380...119,677,819
|
|
G |
BECN1 |
beclin 1 |
increases expression |
ISO |
Trehalose results in increased expression of BECN1 mRNA |
CTD |
PMID:23851366 PMID:30335591 |
|
NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
Trehalose inhibits the reaction [cadmium acetate results in increased expression of CAT protein] |
CTD |
PMID:29140578 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CTSB |
cathepsin B |
multiple interactions increases expression |
ISO |
TFEB affects the reaction [Trehalose results in increased expression of CTSB mRNA] |
CTD |
PMID:30335591 |
|
NCBI chr 8:11,842,524...11,868,087
Ensembl chr 8:11,842,524...11,869,533
|
|
G |
FOXO1 |
forkhead box O1 |
affects localization |
ISO |
Trehalose affects the localization of FOXO1 protein |
CTD |
PMID:23851366 |
|
NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
multiple interactions |
ISO |
Trehalose inhibits the reaction [cadmium acetate results in increased expression of GCLC protein] |
CTD |
PMID:29140578 |
|
NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
|
|
G |
GCLM |
glutamate-cysteine ligase modifier subunit |
multiple interactions |
ISO |
Trehalose inhibits the reaction [cadmium acetate results in increased expression of GCLM protein] |
CTD |
PMID:29140578 |
|
NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456
|
|
G |
GFAP |
glial fibrillary acidic protein |
multiple interactions |
ISO |
Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GFAP protein] |
CTD |
PMID:25064079 |
|
NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Trehalose inhibits the reaction [cadmium acetate results in increased expression of GPX1 protein] |
CTD |
PMID:29140578 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,176...49,358,353
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
ISO |
Trehalose inhibits the reaction [cadmium acetate results in increased expression of GSR protein] |
CTD |
PMID:29140578 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Trehalose inhibits the reaction [cadmium acetate results in increased expression of HMOX1 protein] |
CTD |
PMID:29140578 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HSPB8 |
heat shock protein family B (small) member 8 |
increases expression |
ISO |
Trehalose results in increased expression of HSPB8 mRNA |
CTD |
PMID:30335591 |
|
NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
EXP |
Trehalose inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PARP1 protein] |
CTD |
PMID:23011206 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
KEAP1 |
kelch like ECH associated protein 1 |
multiple interactions |
ISO |
Trehalose inhibits the reaction [cadmium acetate results in decreased expression of KEAP1 protein] |
CTD |
PMID:29140578 |
|
NCBI chr19:10,486,125...10,503,356
Ensembl chr19:10,486,125...10,503,558
|
|
G |
LAMP2 |
lysosomal associated membrane protein 2 |
multiple interactions increases expression |
ISO |
TFEB affects the reaction [Trehalose results in increased expression of LAMP2 mRNA] |
CTD |
PMID:30335591 |
|
NCBI chr X:120,426,148...120,469,349
Ensembl chr X:120,426,148...120,469,365
|
|
G |
MAP1LC3A |
microtubule associated protein 1 light chain 3 alpha |
increases expression |
ISO |
Trehalose results in increased expression of MAP1LC3A mRNA |
CTD |
PMID:23851366 |
|
NCBI chr20:34,546,844...34,560,345
Ensembl chr20:34,546,854...34,560,345
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
increases cleavage increases expression multiple interactions |
ISO |
Trehalose results in increased cleavage of MAP1LC3B protein Trehalose results in increased expression of MAP1LC3B mRNA TFEB affects the reaction [Trehalose results in increased expression of MAP1LC3B mRNA] |
CTD |
PMID:29486218 PMID:30335591 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
MCOLN1 |
mucolipin TRP cation channel 1 |
increases expression multiple interactions |
ISO |
Trehalose results in increased expression of MCOLN1 mRNA TFEB affects the reaction [Trehalose results in increased expression of MCOLN1 mRNA] |
CTD |
PMID:30335591 |
|
NCBI chr19:7,522,624...7,534,009
Ensembl chr19:7,522,624...7,534,009
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
Trehalose inhibits the reaction [cadmium acetate results in increased expression of NQO1 protein] |
CTD |
PMID:29140578 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
OCLN |
occludin |
multiple interactions |
ISO |
Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of OCLN protein] |
CTD |
PMID:25064079 |
|
NCBI chr 5:69,492,547...69,558,104
Ensembl chr 5:69,492,292...69,558,104
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
Trehalose inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PARP1 protein] |
CTD |
PMID:23011206 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
multiple interactions increases expression |
ISO |
TFEB affects the reaction [Trehalose results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:30335591 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PPP3CB |
protein phosphatase 3 catalytic subunit beta |
multiple interactions |
ISO |
PPP3CB affects the reaction [Trehalose affects the localization of TFEB protein] |
CTD |
PMID:30335591 |
|
NCBI chr10:73,436,433...73,496,024
Ensembl chr10:73,436,433...73,496,024
|
|
G |
RPS6KB1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation multiple interactions |
ISO |
Trehalose results in decreased phosphorylation of RPS6KB1 protein Trehalose inhibits the reaction [Cholesterol inhibits the reaction [Cadmium Chloride results in increased cleavage of RPS6KB1 protein]]; Trehalose inhibits the reaction [Cholesterol results in increased phosphorylation of RPS6KB1 protein]; Trehalose inhibits the reaction [Dronabinol results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:29486218 PMID:32773031 |
|
NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574
|
|
G |
SLC2A1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SLC2A1 protein] |
CTD |
PMID:25064079 |
|
NCBI chr 1:42,925,353...42,958,868
Ensembl chr 1:42,925,353...42,958,893
|
|
G |
SLC6A3 |
solute carrier family 6 member 3 |
multiple interactions |
ISO |
Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SLC6A3 protein] |
CTD |
PMID:25064079 |
|
NCBI chr 5:1,392,794...1,445,440
Ensembl chr 5:1,392,794...1,445,440
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
Trehalose inhibits the reaction [cadmium acetate results in increased expression of SOD1 protein] |
CTD |
PMID:29140578 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
Trehalose inhibits the reaction [cadmium acetate results in increased expression of SOD2 protein] |
CTD |
PMID:29140578 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SQSTM1 |
sequestosome 1 |
decreases expression increases expression multiple interactions |
ISO |
Trehalose results in decreased expression of SQSTM1 protein Trehalose results in increased expression of SQSTM1 mRNA TFEB affects the reaction [Trehalose results in increased expression of SQSTM1 mRNA]; Trehalose inhibits the reaction [Dronabinol results in increased expression of SQSTM1 protein] |
CTD |
PMID:23851366 PMID:29486218 PMID:30335591 PMID:32773031 |
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
G |
TFEB |
transcription factor EB |
multiple interactions affects localization |
ISO |
Cyclosporine inhibits the reaction [Trehalose affects the localization of TFEB protein]; PPP3CB affects the reaction [Trehalose affects the localization of TFEB protein]; TFEB affects the reaction [Trehalose results in increased expression of CTSB mRNA]; TFEB affects the reaction [Trehalose results in increased expression of LAMP2 mRNA]; TFEB affects the reaction [Trehalose results in increased expression of MAP1LC3B mRNA]; TFEB affects the reaction [Trehalose results in increased expression of MCOLN1 mRNA]; TFEB affects the reaction [Trehalose results in increased expression of PPARGC1A mRNA]; TFEB affects the reaction [Trehalose results in increased expression of SQSTM1 mRNA]; TFEB affects the reaction [Trehalose results in increased expression of TPP1 mRNA] |
CTD |
PMID:30335591 |
|
NCBI chr 6:41,683,978...41,736,223
Ensembl chr 6:41,683,978...41,736,259
|
|
G |
TJP1 |
tight junction protein 1 |
multiple interactions |
ISO |
Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TJP1 protein] |
CTD |
PMID:25064079 |
|
NCBI chr15:29,699,367...29,969,049
Ensembl chr15:29,699,367...29,968,915
|
|
G |
TPP1 |
tripeptidyl peptidase 1 |
multiple interactions increases expression |
ISO |
TFEB affects the reaction [Trehalose results in increased expression of TPP1 mRNA] |
CTD |
PMID:30335591 |
|
NCBI chr11:6,612,768...6,619,422
Ensembl chr11:6,612,768...6,619,448
|
|
G |
ULK1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
ISO |
Trehalose inhibits the reaction [Dronabinol results in increased phosphorylation of ULK1 protein] |
CTD |
PMID:32773031 |
|
NCBI chr12:131,894,622...131,923,150
Ensembl chr12:131,894,622...131,923,150
|
|
G |
ZKSCAN3 |
zinc finger with KRAB and SCAN domains 3 |
increases expression |
ISO |
Trehalose results in increased expression of ZKSCAN3 mRNA |
CTD |
PMID:30335591 |
|
NCBI chr 6:28,349,878...28,369,172
Ensembl chr 6:28,349,947...28,369,172
|
|
|
G |
MGAM |
maltase-glucoamylase |
multiple interactions increases metabolic processing |
ISO |
[MGAM protein results in increased metabolism of Maltose] which results in increased abundance of Glucose |
CTD |
PMID:17585022 |
|
NCBI chr 7:141,986,518...142,106,747
Ensembl chr 7:141,907,813...142,106,747
|
|
G |
SLC2A2 |
solute carrier family 2 member 2 |
multiple interactions |
EXP |
Maltose inhibits the reaction [SLC2A2 protein results in increased transport of Deoxyglucose]; Maltose inhibits the reaction [SLC2A2 protein results in increased transport of Fructose] |
CTD |
PMID:8457197 |
|
NCBI chr 3:170,996,347...171,026,720
Ensembl chr 3:170,996,347...171,026,743
|
|
G |
SLC2A3 |
solute carrier family 2 member 3 |
multiple interactions |
EXP |
Maltose inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose]; Maltose inhibits the reaction [SLC2A3 protein results in increased transport of Galactose] |
CTD |
PMID:8457197 |
|
NCBI chr12:7,919,230...7,936,187
Ensembl chr12:7,919,230...7,936,187
|
|
|
G |
ACP5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
crocin promotes the reaction [pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein]] |
CTD |
PMID:30580027 |
|
NCBI chr19:11,574,660...11,578,975
Ensembl chr19:11,574,653...11,579,993
|
|
G |
AKT2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA] |
CTD |
PMID:30580027 |
|
NCBI chr19:40,230,317...40,285,345
Ensembl chr19:40,230,317...40,285,536
|
|
G |
BAMBI |
BMP and activin membrane bound inhibitor |
multiple interactions |
ISO |
crocin inhibits the reaction [Cisplatin results in decreased expression of BAMBI mRNA] |
CTD |
PMID:32259551 |
|
NCBI chr10:28,677,521...28,682,932
Ensembl chr10:28,677,510...28,682,932
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX protein]; crocin inhibits the reaction [Diazinon results in increased expression of BAX mRNA]; crocin inhibits the reaction [Diazinon results in increased expression of BAX protein] crocin results in increased expression of BAX mRNA |
CTD |
PMID:23523949 PMID:27353299 PMID:32886819 PMID:32920515 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions decreases expression |
ISO EXP |
[crocin co-treated with Paraquat] results in decreased expression of BCL2 mRNA crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein] crocin results in decreased expression of BCL2 mRNA |
CTD |
PMID:31911963 PMID:32886819 PMID:32920515 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BDNF |
brain derived neurotrophic factor |
increases expression |
ISO |
crocin results in increased expression of BDNF mRNA; crocin results in increased expression of BDNF protein |
CTD |
PMID:24401376 |
|
NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
decreases expression |
EXP |
crocin results in decreased expression of BIRC5 mRNA |
CTD |
PMID:32886819 |
|
NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases activity increases expression increases cleavage |
ISO EXP |
crocin affects the reaction [Ethanol results in increased expression of CASP3 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein]; crocin inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein]; crocin inhibits the reaction [Diazinon results in increased activity of CASP3 protein]; crocin inhibits the reaction [Diazinon results in increased cleavage of CASP3 protein]; crocin inhibits the reaction [Diazinon results in increased expression of CASP3 protein modified form]; crocin inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; crocin inhibits the reaction [Ethanol results in increased activity of CASP3 protein] crocin results in increased activity of CASP3 protein crocin results in increased expression of CASP3 mRNA crocin inhibits the reaction [Paraquat results in increased expression of CASP3 mRNA] Acetylcysteine inhibits the reaction [crocin results in increased activity of CASP3 protein]; MIR34A mRNA inhibits the reaction [crocin results in increased activity of CASP3 protein]; MYCN protein inhibits the reaction [crocin results in increased cleavage of CASP3 protein]; PTPN4 protein affects the reaction [crocin results in increased activity of CASP3 protein] |
CTD |
PMID:23523949 PMID:25637687 PMID:25899501 PMID:26807765 PMID:27353299 PMID:30672053 PMID:31911963 PMID:32886819 PMID:32920515 PMID:35085590 More...
|
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
CASP8 |
caspase 8 |
increases activity |
EXP |
crocin results in increased activity of CASP8 protein |
CTD |
PMID:32886819 |
|
NCBI chr 2:201,233,443...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
multiple interactions increases activity |
ISO EXP |
crocin inhibits the reaction [Diazinon results in increased cleavage of CASP9 protein] crocin results in increased activity of CASP9 protein |
CTD |
PMID:27353299 PMID:32886819 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions decreases activity increases activity |
ISO EXP |
crocin inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein]; crocin inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]; crocin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] crocin results in decreased activity of CAT protein crocin inhibits the reaction [Patulin results in increased activity of CAT protein] crocin results in increased activity of CAT protein |
CTD |
PMID:25899501 PMID:26584762 PMID:29409856 PMID:32886819 PMID:32920515 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCND1 |
cyclin D1 |
decreases expression |
EXP |
crocin results in decreased expression of CCND1 mRNA |
CTD |
PMID:32886819 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CKM |
creatine kinase, M-type |
multiple interactions |
ISO |
crocin inhibits the reaction [Diazinon results in increased activity of CKM protein] |
CTD |
PMID:23523949 |
|
NCBI chr19:45,306,413...45,322,875
Ensembl chr19:45,306,413...45,322,875
|
|
G |
COL2A1 |
collagen type II alpha 1 chain |
multiple interactions |
ISO |
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of phenylpyruvic acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Citric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Succinic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein] |
CTD |
PMID:24709313 |
|
NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
crocin results in increased expression of and results in increased phosphorylation of CREB1 protein |
CTD |
PMID:24401376 |
|
NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions |
ISO |
crocin inhibits the reaction [Diazinon affects the localization of CYCS protein] |
CTD |
PMID:23523949 |
|
NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions decreases activity |
ISO |
crocin inhibits the reaction [Carbon Tetrachloride results in increased activity of CYP2E1 protein] crocin results in decreased activity of CYP2E1 protein |
CTD |
PMID:25899501 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
GLO1 |
glyoxalase I |
multiple interactions |
ISO |
crocin inhibits the reaction [[TNFSF11 protein co-treated with Pyruvaldehyde] results in decreased activity of GLO1 protein] |
CTD |
PMID:30580027 |
|
NCBI chr 6:38,675,925...38,703,145
Ensembl chr 6:38,675,925...38,703,145
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
crocin inhibits the reaction [Cisplatin results in increased activity of GPT protein] |
CTD |
PMID:32259551 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions |
ISO |
crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of HMOX1 protein] |
CTD |
PMID:32920515 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HSPA1L |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
ISO |
crocin inhibits the reaction [Ethanol results in increased expression of HSPA1L mRNA] |
CTD |
PMID:25637687 |
|
NCBI chr 6:31,809,619...31,815,283
Ensembl chr 6:31,809,619...31,815,283
|
|
G |
IL10 |
interleukin 10 |
multiple interactions |
ISO |
crocin inhibits the reaction [Doxorubicin results in decreased expression of IL10 protein] |
CTD |
PMID:26807765 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein]; crocin inhibits the reaction [Doxorubicin results in increased expression of IL1B protein] |
CTD |
PMID:24709313 PMID:26807765 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions decreases expression |
ISO EXP |
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of IL6 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of IL6 protein]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; crocin inhibits the reaction [Ethanol results in decreased expression of IL6 protein]; crocin inhibits the reaction [Streptozocin results in increased expression of IL6 protein] crocin results in decreased expression of IL6 mRNA |
CTD |
PMID:25637687 PMID:25899501 PMID:29409856 PMID:32886819 PMID:32920515 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
JAK2 |
Janus kinase 2 |
multiple interactions |
EXP |
crocin affects the expression of and affects the phosphorylation of JAK2 protein |
CTD |
PMID:32886819 |
|
NCBI chr 9:4,984,390...5,129,948
Ensembl chr 9:4,984,390...5,129,948
|
|
G |
KEAP1 |
kelch like ECH associated protein 1 |
multiple interactions |
ISO |
crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of KEAP1 protein] |
CTD |
PMID:32920515 |
|
NCBI chr19:10,486,125...10,503,356
Ensembl chr19:10,486,125...10,503,558
|
|
G |
LDLR |
low density lipoprotein receptor |
multiple interactions |
ISO |
crocin inhibits the reaction [Diazinon results in decreased expression of LDLR mRNA] |
CTD |
PMID:24132704 |
|
NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,462...11,133,820
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
crocin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; crocin inhibits the reaction [Diazinon results in decreased phosphorylation of MAPK1 protein] crocin results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:24132704 PMID:28689058 PMID:32886819 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO EXP |
crocin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; crocin inhibits the reaction [Diazinon results in decreased phosphorylation of MAPK3 protein] crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA] crocin results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:24132704 PMID:28689058 PMID:30580027 PMID:32886819 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MIR122 |
microRNA 122 |
multiple interactions |
ISO |
crocin inhibits the reaction [bisphenol A results in increased expression of MIR122 mRNA] |
CTD |
PMID:28689058 |
|
NCBI chr18:58,451,074...58,451,158
Ensembl chr18:58,451,074...58,451,158
|
|
G |
MIR29B1 |
microRNA 29b-1 |
multiple interactions increases expression |
ISO |
Cisplatin inhibits the reaction [crocin results in increased expression of MIR29B1 mRNA]; crocin inhibits the reaction [Cisplatin results in decreased expression of MIR29B1 mRNA] |
CTD |
PMID:32259551 |
|
NCBI chr 7:130,877,459...130,877,539
Ensembl chr 7:130,877,459...130,877,539
|
|
G |
MIR34A |
microRNA 34a |
multiple interactions |
EXP |
MIR34A mRNA inhibits the reaction [crocin results in increased activity of CASP3 protein]; MIR34A mRNA inhibits the reaction [crocin results in increased expression of PTPN4 protein] |
CTD |
PMID:35085590 |
|
NCBI chr 1:9,151,668...9,151,777
Ensembl chr 1:9,151,668...9,151,777
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
crocin inhibits the reaction [Ethanol results in increased activity of MPO protein] |
CTD |
PMID:25637687 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
EXP |
crocin results in decreased expression of MYC mRNA |
CTD |
PMID:32886819 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
MYCN |
MYCN proto-oncogene, bHLH transcription factor |
multiple interactions decreases response to substance decreases expression |
EXP |
crocin results in decreased expression of and results in decreased stability of MYCN mRNA; MYCN protein inhibits the reaction [crocin results in increased cleavage of CASP3 protein]; MYCN protein inhibits the reaction [crocin results in increased cleavage of PARP1 protein] MYCN results in decreased susceptibility to crocin crocin results in decreased expression of MYCN protein |
CTD |
PMID:30672053 |
|
NCBI chr 2:15,940,550...15,947,004
Ensembl chr 2:15,940,550...15,947,007
|
|
G |
MYD88 |
MYD88 innate immune signal transduction adaptor |
multiple interactions |
ISO |
crocin inhibits the reaction [Cisplatin results in increased expression of MYD88 mRNA]; crocin inhibits the reaction [Cisplatin results in increased expression of MYD88 protein] |
CTD |
PMID:32259551 |
|
NCBI chr 3:38,138,661...38,143,022
Ensembl chr 3:38,138,478...38,143,022
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of NFE2L2 protein]; crocin inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 protein] |
CTD |
PMID:32259551 PMID:32920515 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,227,595...177,392,697
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of NQO1 protein] |
CTD |
PMID:32920515 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
OSTM1 |
osteoclastogenesis associated transmembrane protein 1 |
multiple interactions |
ISO |
[crocin co-treated with pyrazolanthrone co-treated with TNFSF11 protein] results in decreased expression of OSTM1 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA] |
CTD |
PMID:30580027 |
|
NCBI chr 6:108,041,409...108,074,741
Ensembl chr 6:108,041,409...108,165,854
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
EXP |
MYCN protein inhibits the reaction [crocin results in increased cleavage of PARP1 protein] |
CTD |
PMID:30672053 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
EXP |
crocin results in decreased expression of PTGS2 mRNA |
CTD |
PMID:32886819 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
PTPN4 |
protein tyrosine phosphatase non-receptor type 4 |
increases expression multiple interactions |
EXP |
crocin results in increased expression of PTPN4 protein MIR34A mRNA inhibits the reaction [crocin results in increased expression of PTPN4 protein]; PTPN4 protein affects the reaction [crocin results in increased activity of CASP3 protein] |
CTD |
PMID:35085590 |
|
NCBI chr 2:119,759,922...119,984,899
Ensembl chr 2:119,759,922...119,984,899
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of RELA protein]; crocin inhibits the reaction [Streptozocin results in increased expression of RELA protein] |
CTD |
PMID:29409856 PMID:32920515 |
|
NCBI chr11:65,653,601...65,662,916
Ensembl chr11:65,653,599...65,663,090
|
|
G |
SMAD2 |
SMAD family member 2 |
multiple interactions decreases expression |
ISO |
Cisplatin inhibits the reaction [crocin results in decreased expression of SMAD2 protein]; crocin inhibits the reaction [Cisplatin results in increased expression of SMAD2 protein] |
CTD |
PMID:32259551 |
|
NCBI chr18:47,808,957...47,930,872
Ensembl chr18:47,808,957...47,931,146
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
crocin affects the expression of and affects the phosphorylation of STAT3 protein |
CTD |
PMID:32886819 |
|
NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,540
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions |
ISO |
crocin inhibits the reaction [Cisplatin results in increased expression of TGFB1 protein]; crocin inhibits the reaction [Streptozocin results in increased expression of TGFB1 protein] |
CTD |
PMID:29409856 PMID:32259551 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TGFBR1 |
transforming growth factor beta receptor 1 |
multiple interactions |
ISO |
crocin inhibits the reaction [Cisplatin results in increased expression of TGFBR1 protein] |
CTD |
PMID:32259551 |
|
NCBI chr 9:99,104,038...99,154,192
Ensembl chr 9:99,104,038...99,154,192
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions |
ISO |
crocin inhibits the reaction [Cisplatin results in increased expression of TLR4 mRNA]; crocin inhibits the reaction [Cisplatin results in increased expression of TLR4 protein]; crocin inhibits the reaction [Streptozocin results in increased expression of TLR4 protein] |
CTD |
PMID:29409856 PMID:32259551 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; crocin inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; crocin inhibits the reaction [Ethanol results in decreased expression of TNF protein] crocin results in decreased expression of TNF mRNA |
CTD |
PMID:25637687 PMID:25899501 PMID:26807765 PMID:32886819 PMID:32920515 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFSF11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
[crocin co-treated with pyrazolanthrone co-treated with TNFSF11 protein] results in decreased expression of OSTM1 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with Pyruvaldehyde] results in decreased activity of GLO1 protein]; crocin promotes the reaction [pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein]] |
CTD |
PMID:30580027 |
|
NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
|
|
G |
TNNT2 |
troponin T2, cardiac type |
multiple interactions |
ISO |
crocin inhibits the reaction [Doxorubicin results in increased expression of TNNT2 protein] |
CTD |
PMID:26807765 |
|
NCBI chr 1:201,359,014...201,377,680
Ensembl chr 1:201,359,008...201,377,764
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
ISO |
crocin inhibits the reaction [Paraquat results in increased expression of TRP53 mRNA] |
CTD |
PMID:31911963 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
|
|
G |
TRAF6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA] |
CTD |
PMID:30580027 |
|
NCBI chr11:36,483,769...36,510,272
Ensembl chr11:36,483,769...36,510,272
|
|
G |
VGF |
VGF nerve growth factor inducible |
increases expression |
ISO |
crocin results in increased expression of VGF protein |
CTD |
PMID:24401376 |
|
NCBI chr 7:101,162,509...101,169,952
Ensembl chr 7:101,162,509...101,165,569
|
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions |
ISO EXP |
Diosmin binds to and results in increased activity of AHR protein |
CTD |
PMID:14644660 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
BAD |
BCL2 associated agonist of cell death |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Lipopolysaccharides results in increased expression of BAD protein] |
CTD |
PMID:21477647 |
|
NCBI chr11:64,269,828...64,284,704
Ensembl chr11:64,269,830...64,284,704
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of BAX protein] |
CTD |
PMID:32061149 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO |
[Diosmin co-treated with Lipopolysaccharides] results in increased expression of BCL2 protein Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of BCL2 protein] |
CTD |
PMID:21477647 PMID:32061149 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP3 protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of CASP3 protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of CASP3 protein] |
CTD |
PMID:21477647 PMID:23665045 PMID:29187079 PMID:32061149 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
CASP7 |
caspase 7 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP7 protein] |
CTD |
PMID:23665045 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP9 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in decreased expression of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein] |
CTD |
PMID:22056647 PMID:23665045 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of CYP2E1 protein] |
CTD |
PMID:23665045 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in decreased expression of GSR protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of GSR protein] |
CTD |
PMID:23665045 PMID:32061149 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of IL6 protein] |
CTD |
PMID:32061149 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
MKI67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of MKI67 protein]; Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of MKI67 protein] |
CTD |
PMID:23665045 |
|
NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Acetic Acid results in increased activity of MPO protein] |
CTD |
PMID:29187079 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of NOS2 protein] |
CTD |
PMID:23665045 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of PARP1 protein] |
CTD |
PMID:32061149 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PCNA |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of PCNA protein]; Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of PCNA protein] |
CTD |
PMID:23665045 |
|
NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of PTGS2 protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of PTGS2 protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 protein] |
CTD |
PMID:23665045 PMID:29187079 PMID:32061149 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of RELA protein] |
CTD |
PMID:32061149 |
|
NCBI chr11:65,653,601...65,662,916
Ensembl chr11:65,653,599...65,663,090
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of TNF protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:21477647 PMID:23665045 PMID:29187079 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of TP53 protein] |
CTD |
PMID:23665045 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
|
|
G |
XDH |
xanthine dehydrogenase |
multiple interactions |
ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of XDH protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of XDH protein] |
CTD |
PMID:23665045 PMID:32061149 |
|
NCBI chr 2:31,334,321...31,414,742
Ensembl chr 2:31,334,321...31,414,742
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
decreases activity |
ISO |
eprinomectin results in decreased activity of ABCB1A protein |
CTD |
PMID:17134887 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ANO1 |
anoctamin 1 |
decreases activity |
ISO |
eprinomectin results in decreased activity of ANO1 protein |
CTD |
PMID:32201246 |
|
NCBI chr11:69,965,997...70,189,530
Ensembl chr11:69,985,907...70,189,530
|
|
G |
NCOA2 |
nuclear receptor coactivator 2 |
multiple interactions |
EXP |
eprinomectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]] |
CTD |
PMID:27773686 |
|
NCBI chr 8:70,109,782...70,456,446
Ensembl chr 8:70,109,782...70,403,808
|
|
G |
NR1H4 |
nuclear receptor subfamily 1 group H member 4 |
multiple interactions |
EXP |
eprinomectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]] |
CTD |
PMID:27773686 |
|
NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
eriocitrin results in increased expression of BAX protein |
CTD |
PMID:34724282 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression |
EXP |
eriocitrin results in decreased expression of BCL2 protein |
CTD |
PMID:34724282 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
CASP7 |
caspase 7 |
increases expression |
EXP |
eriocitrin results in increased expression of CASP7 protein |
CTD |
PMID:34724282 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CASP9 |
caspase 9 |
increases expression |
EXP |
eriocitrin results in increased expression of CASP9 protein |
CTD |
PMID:34724282 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CCND1 |
cyclin D1 |
decreases expression |
EXP |
eriocitrin results in decreased expression of CCND1 protein |
CTD |
PMID:34724282 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
JAK2 |
Janus kinase 2 |
decreases phosphorylation |
EXP |
eriocitrin results in decreased phosphorylation of JAK2 protein |
CTD |
PMID:34724282 |
|
NCBI chr 9:4,984,390...5,129,948
Ensembl chr 9:4,984,390...5,129,948
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
EXP |
Acetylcysteine inhibits the reaction [eriocitrin results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:34724282 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
PCNA |
proliferating cell nuclear antigen |
decreases expression |
EXP |
eriocitrin results in decreased expression of PCNA protein |
CTD |
PMID:34724282 |
|
NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
|
|
G |
SRC |
SRC proto-oncogene, non-receptor tyrosine kinase |
decreases phosphorylation |
EXP |
eriocitrin results in decreased phosphorylation of SRC protein |
CTD |
PMID:34724282 |
|
NCBI chr20:37,344,699...37,406,050
Ensembl chr20:37,344,685...37,406,050
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation |
EXP |
eriocitrin results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:34724282 |
|
NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,540
|
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
ginsenoside Rb2 results in increased expression of ABCC2 mRNA |
CTD |
PMID:23835644 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
LPL |
lipoprotein lipase |
increases secretion decreases secretion |
ISO |
ginsenoside Rb2 results in increased secretion of LPL protein ginsenoside Rb2 results in decreased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259
|
|
|
G |
SLCO1B3 |
solute carrier organic anion transporter family member 1B3 |
multiple interactions |
EXP |
ginsenoside Rc binds to and results in decreased activity of SLCO1B3 protein |
CTD |
PMID:25297453 |
|
NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911
|
|
|
G |
ABCB11 |
ATP binding cassette subfamily B member 11 |
increases transport |
ISO EXP |
ABCB11 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
|
|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 |
increases transport |
EXP |
ABCC1 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
increases transport |
ISO EXP |
ABCC2 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCG2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
increases transport |
ISO EXP |
ABCG2 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
increases expression multiple interactions |
ISO |
ginsenoside Re results in increased expression of ADIPOQ mRNA ginsenoside Re results in increased expression of and results in increased secretion of ADIPOQ protein |
CTD |
PMID:23545455 |
|
NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463
|
|
G |
AIF1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO |
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of AIF1 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]] |
CTD |
PMID:29467000 |
|
NCBI chr 6:31,615,234...31,617,015
Ensembl chr 6:31,615,217...31,617,021
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO |
ginsenoside Re results in increased phosphorylation of and results in increased activity of AKT1 protein ginsenoside Re results in increased phosphorylation of AKT1 protein |
CTD |
PMID:17878692 PMID:17885204 PMID:24599032 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
AR |
androgen receptor |
multiple interactions |
EXP |
ginsenoside Re binds to and affects the activity of AR protein |
CTD |
PMID:16985185 |
|
NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
decreases expression multiple interactions |
ISO |
ginsenoside Re results in decreased expression of BAX mRNA; ginsenoside Re results in decreased expression of BAX protein 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of BAX protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]] |
CTD |
PMID:12674765 PMID:15621629 PMID:29467000 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
increases expression multiple interactions |
ISO |
ginsenoside Re results in increased expression of BCL2 mRNA; ginsenoside Re results in increased expression of BCL2 protein 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of BCL2 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]] |
CTD |
PMID:15621629 PMID:29467000 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO EXP |
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re results in decreased cleavage of and results in decreased activity of CASP3 protein; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]] |
CTD |
PMID:15621629 PMID:23102375 PMID:25523949 PMID:29467000 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]] |
CTD |
PMID:24430743 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression |
ISO |
ginsenoside Re results in increased expression of CDKN1A mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
|
|
G |
CHAT |
choline O-acetyltransferase |
increases expression multiple interactions |
ISO |
ginsenoside Re results in increased expression of CHAT mRNA; ginsenoside Re results in increased expression of CHAT protein staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT protein] |
CTD |
PMID:24599032 |
|
NCBI chr10:49,609,095...49,667,942
Ensembl chr10:49,609,095...49,667,942
|
|
G |
CHUK |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of CHUK protein] |
CTD |
PMID:17885204 |
|
NCBI chr10:100,186,319...100,229,596
Ensembl chr10:100,188,300...100,229,596
|
|
G |
CLDN1 |
claudin 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of CLDN1 protein] |
CTD |
PMID:22849695 |
|
NCBI chr 3:190,305,707...190,322,446
Ensembl chr 3:190,305,707...190,322,446
|
|
G |
CRP |
C-reactive protein |
increases expression |
ISO |
ginsenoside Re results in increased expression of CRP protein |
CTD |
PMID:16797897 |
|
NCBI chr 1:159,712,289...159,714,589
Ensembl chr 1:159,712,289...159,714,589
|
|
G |
CYBA |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [Phencyclidine results in increased activity of CYBA protein] |
CTD |
PMID:29037473 |
|
NCBI chr16:88,643,289...88,651,053
Ensembl chr16:88,643,275...88,651,083
|
|
G |
CYP8B1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression |
ISO |
ginsenoside Re results in increased expression of CYP8B1 mRNA |
CTD |
PMID:23835644 |
|
NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898
|
|
G |
ESR1 |
estrogen receptor 1 |
multiple interactions |
EXP |
ginsenoside Re binds to and affects the activity of ESR1 protein |
CTD |
PMID:16985185 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
FABP4 |
fatty acid binding protein 4 |
increases expression |
ISO |
ginsenoside Re results in increased expression of FABP4 mRNA |
CTD |
PMID:23545455 |
|
NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236
|
|
G |
FAS |
Fas cell surface death receptor |
decreases expression multiple interactions |
EXP ISO |
ginsenoside Re results in decreased expression of FAS mRNA ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA] |
CTD |
PMID:21971952 |
|
NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
ginsenoside Re results in increased expression of FOS mRNA |
CTD |
PMID:16204943 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
G6PC1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
EXP |
ginsenoside Re results in decreased expression of G6PC1 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438
|
|
G |
GPAM |
glycerol-3-phosphate acyltransferase, mitochondrial |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of GPAM mRNA] |
CTD |
PMID:21971952 |
|
NCBI chr10:112,149,865...112,227,677
Ensembl chr10:112,149,865...112,215,377
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]] |
CTD |
PMID:29037473 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,176...49,358,353
|
|
G |
GSK3B |
glycogen synthase kinase 3 beta |
increases phosphorylation |
ISO |
ginsenoside Re results in increased phosphorylation of GSK3B protein |
CTD |
PMID:17885204 |
|
NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994
|
|
G |
HSPD1 |
heat shock protein family D (Hsp60) member 1 |
increases expression |
ISO |
ginsenoside Re results in increased expression of HSPD1 protein |
CTD |
PMID:23144451 |
|
NCBI chr 2:197,486,584...197,500,274
Ensembl chr 2:197,486,584...197,516,737
|
|
G |
IFNG |
interferon gamma |
decreases expression |
EXP |
ginsenoside Re results in decreased expression of IFNG protein |
CTD |
PMID:20230918 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IKBKB |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:22849695 |
|
NCBI chr 8:42,271,302...42,332,460
Ensembl chr 8:42,271,302...42,332,460
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA] |
CTD |
PMID:16557482 PMID:22494059 PMID:22849695 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [TNF protein results in increased expression of IL6 mRNA] |
CTD |
PMID:17885204 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
IRAK1 |
interleukin 1 receptor associated kinase 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased degradation of IRAK1 protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRAK1 protein] |
CTD |
PMID:22849695 |
|
NCBI chr X:154,010,507...154,019,902
Ensembl chr X:154,010,506...154,019,902
|
|
G |
IRAK4 |
interleukin 1 receptor associated kinase 4 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased degradation of IRAK4 protein] |
CTD |
PMID:22849695 |
|
NCBI chr12:43,758,951...43,789,541
Ensembl chr12:43,758,944...43,798,307
|
|
G |
IRGM |
immunity related GTPase M |
decreases expression |
EXP |
ginsenoside Re results in decreased expression of IRGM protein |
CTD |
PMID:20230918 |
|
NCBI chr 5:150,846,521...150,902,402
Ensembl chr 5:150,846,521...150,900,736
|
|
G |
IRS1 |
insulin receptor substrate 1 |
multiple interactions increases expression increases phosphorylation |
ISO |
ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein] ginsenoside Re results in increased expression of IRS1 mRNA ginsenoside Re results in increased phosphorylation of IRS1 protein |
CTD |
PMID:17885204 PMID:23545455 |
|
NCBI chr 2:226,731,312...226,799,820
Ensembl chr 2:226,731,312...226,799,820
|
|
G |
KCNE1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
increases expression |
EXP |
ginsenoside Re results in increased expression of KCNE1 |
CTD |
PMID:24615935 |
|
NCBI chr21:34,446,688...34,512,210
Ensembl chr21:34,446,688...34,512,214
|
|
G |
LPL |
lipoprotein lipase |
increases secretion |
ISO |
ginsenoside Re results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259
|
|
G |
LRPPRC |
leucine rich pentatricopeptide repeat containing |
increases expression |
ISO |
ginsenoside Re results in increased expression of LRPPRC protein |
CTD |
PMID:23144451 |
|
NCBI chr 2:43,886,224...43,996,265
Ensembl chr 2:43,886,224...43,996,226
|
|
G |
MAP2 |
microtubule associated protein 2 |
increases expression |
ISO |
ginsenoside Re results in increased expression of MAP2 mRNA; ginsenoside Re results in increased expression of MAP2 protein |
CTD |
PMID:24599032 |
|
NCBI chr 2:209,424,047...209,734,112
Ensembl chr 2:209,424,047...209,734,118
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK1 protein |
CTD |
PMID:24599032 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:24599032 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:22849695 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
MYL9 |
myosin light chain 9 |
affects phosphorylation |
ISO |
ginsenoside Re affects the phosphorylation of MYL9 protein |
CTD |
PMID:24658813 |
|
NCBI chr20:36,541,519...36,551,447
Ensembl chr20:36,541,497...36,551,447
|
|
G |
MYLK |
myosin light chain kinase |
affects expression |
ISO |
ginsenoside Re affects the expression of MYLK mRNA; ginsenoside Re affects the expression of MYLK protein |
CTD |
PMID:24658813 |
|
NCBI chr 3:123,610,049...123,884,332
Ensembl chr 3:123,610,049...123,884,332
|
|
G |
NCF1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [Phencyclidine affects the localization of NCF1 protein] |
CTD |
PMID:29037473 |
|
NCBI chr 7:74,774,011...74,789,315
Ensembl chr 7:74,774,011...74,789,315
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein] |
CTD |
PMID:17885204 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,513...35,404,749
|
|
G |
NGF |
nerve growth factor |
increases expression |
ISO |
ginsenoside Re results in increased expression of NGF mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 1:115,285,917...115,338,249
Ensembl chr 1:115,285,904...115,338,770
|
|
G |
NGFR |
nerve growth factor receptor |
increases expression |
ISO |
ginsenoside Re results in increased expression of NGFR mRNA; ginsenoside Re results in increased expression of NGFR protein |
CTD |
PMID:24599032 |
|
NCBI chr17:49,495,293...49,515,008
Ensembl chr17:49,495,293...49,515,008
|
|
G |
NOS2 |
nitric oxide synthase 2 |
decreases expression multiple interactions |
ISO |
ginsenoside Re results in decreased expression of NOS2 protein ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:15621629 PMID:23102375 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions increases phosphorylation |
EXP |
2-aminoethoxydiphenyl borate inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Calcium deficiency inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Mifepristone inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein] |
CTD |
PMID:17490654 |
|
NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
|
|
G |
NR0B2 |
nuclear receptor subfamily 0 group B member 2 |
increases expression |
EXP |
ginsenoside Re results in increased expression of NR0B2 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975
|
|
G |
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
multiple interactions increases activity |
EXP |
[ginsenoside Re results in increased activity of NR3C1 protein] which results in increased abundance of Nitric Oxide |
CTD |
PMID:17490654 |
|
NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512
|
|
G |
OCLN |
occludin |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of OCLN protein] |
CTD |
PMID:22849695 |
|
NCBI chr 5:69,492,547...69,558,104
Ensembl chr 5:69,492,292...69,558,104
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Methamphetamine results in increased cleavage of PARP1 protein] |
CTD |
PMID:25523949 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PCK1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions decreases expression |
ISO EXP |
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of PCK1 mRNA] ginsenoside Re results in decreased expression of PCK1 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121
|
|
G |
PDYN |
prodynorphin |
multiple interactions |
ISO |
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of PDYN mRNA]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]] |
CTD |
PMID:29467000 |
|
NCBI chr20:1,978,756...1,994,285
Ensembl chr20:1,978,757...1,994,285
|
|
G |
PGR |
progesterone receptor |
multiple interactions increases expression |
EXP |
ginsenoside Re binds to and affects the activity of PGR protein ginsenoside Re results in increased expression of PGR protein |
CTD |
PMID:16204943 PMID:16985185 |
|
NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
increases expression |
ISO |
ginsenoside Re results in increased expression of PPARG mRNA |
CTD |
PMID:23545455 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PRKAA1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation multiple interactions |
EXP ISO |
ginsenoside Re results in increased phosphorylation of PRKAA1 protein ginsenoside Re inhibits the reaction [Dietary Fats results in decreased phosphorylation of PRKAA1 protein] |
CTD |
PMID:21971952 |
|
NCBI chr 5:40,759,389...40,798,374
Ensembl chr 5:40,759,389...40,798,374
|
|
G |
PRKCD |
protein kinase C delta |
multiple interactions increases response to substance |
ISO EXP |
ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]] ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of and results in increased cleavage of PRKCD protein] PRKCD results in increased susceptibility to ginsenoside Re |
CTD |
PMID:24430743 PMID:25523949 |
|
NCBI chr 3:53,161,209...53,192,717
Ensembl chr 3:53,156,009...53,192,717
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16557482 PMID:23102375 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
RPS6KB1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation |
ISO |
ginsenoside Re results in increased phosphorylation of RPS6KB1 protein |
CTD |
PMID:17885204 |
|
NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574
|
|
G |
SCD |
stearoyl-CoA desaturase |
decreases expression |
EXP |
ginsenoside Re results in decreased expression of SCD mRNA |
CTD |
PMID:21971952 |
|
NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826
|
|
G |
SLC18A3 |
solute carrier family 18 member A3 |
increases expression |
ISO |
ginsenoside Re results in increased expression of SLC18A3 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr10:49,610,310...49,612,720
Ensembl chr10:49,610,310...49,612,720
|
|
G |
SLC2A4 |
solute carrier family 2 member 4 |
multiple interactions increases localization |
ISO |
ginsenoside Re inhibits the reaction [Dietary Fats inhibits the reaction [INS1 protein results in increased localization of SLC2A4 protein]] ginsenoside Re results in increased localization of SLC2A4 protein |
CTD |
PMID:17885204 PMID:22571876 PMID:23545455 |
|
NCBI chr17:7,281,718...7,288,257
Ensembl chr17:7,281,718...7,288,257
|
|
G |
SLC5A7 |
solute carrier family 5 member 7 |
increases expression |
ISO |
ginsenoside Re results in increased expression of SLC5A7 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 2:107,986,524...108,013,994
Ensembl chr 2:107,986,523...108,013,994
|
|
G |
SLCO1B3 |
solute carrier organic anion transporter family member 1B3 |
multiple interactions |
EXP ISO |
SLCO1B3 protein binds to and results in increased transport of ginsenoside Re SLCO1B2 protein binds to and results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911
|
|
G |
SOCS3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [TNF protein results in increased expression of SOCS3 mRNA] |
CTD |
PMID:17885204 |
|
NCBI chr17:78,356,778...78,360,925
Ensembl chr17:78,356,778...78,360,077
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]] |
CTD |
PMID:24430743 PMID:29037473 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]] |
CTD |
PMID:29037473 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression |
ISO EXP |
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] ginsenoside Re results in decreased expression of SREBF1 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
STK11 |
serine/threonine kinase 11 |
increases phosphorylation |
EXP |
ginsenoside Re results in increased phosphorylation of STK11 protein |
CTD |
PMID:21971952 |
|
NCBI chr19:1,205,778...1,228,431
Ensembl chr19:1,177,558...1,228,431
|
|
G |
TAC1 |
tachykinin precursor 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]] |
CTD |
PMID:29467000 |
|
NCBI chr 7:97,732,086...97,740,472
Ensembl chr 7:97,732,084...97,740,472
|
|
G |
TBC1D4 |
TBC1 domain family member 4 |
increases phosphorylation |
ISO |
ginsenoside Re results in increased phosphorylation of TBC1D4 protein |
CTD |
PMID:17885204 |
|
NCBI chr13:75,283,503...75,482,169
Ensembl chr13:75,283,503...75,482,169
|
|
G |
TFF1 |
trefoil factor 1 |
increases expression |
EXP |
ginsenoside Re results in increased expression of TFF1 mRNA |
CTD |
PMID:16204943 |
|
NCBI chr21:42,362,282...42,366,535
Ensembl chr21:42,362,282...42,366,535
|
|
G |
TH |
tyrosine hydroxylase |
multiple interactions |
EXP ISO |
ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of and results in decreased activity of TH protein] 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of TH protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]] |
CTD |
PMID:25523949 PMID:29467000 |
|
NCBI chr11:2,163,929...2,171,815
Ensembl chr11:2,163,929...2,171,815
|
|
G |
TJP1 |
tight junction protein 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of TJP1 protein] |
CTD |
PMID:22849695 |
|
NCBI chr15:29,699,367...29,969,049
Ensembl chr15:29,699,367...29,968,915
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides binds to TLR4 protein] |
CTD |
PMID:22849695 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of SOCS3 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of CHUK protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA]; ginsenoside Re results in decreased expression of and results in decreased secretion of TNF protein |
CTD |
PMID:16557482 PMID:17885204 PMID:22494059 PMID:22849695 PMID:23545455 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
|
G |
APOA1 |
apolipoprotein A1 |
multiple interactions decreases expression |
ISO |
ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]] ginsenoside Rf results in decreased expression of APOA1 protein |
CTD |
PMID:16297877 |
|
NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622
|
|
G |
APOC3 |
apolipoprotein C3 |
multiple interactions decreases expression increases expression |
ISO |
ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA] ginsenoside Rf results in decreased expression of APOC3 protein |
CTD |
PMID:16297877 |
|
NCBI chr11:116,829,907...116,833,072
Ensembl chr11:116,829,706...116,833,072
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity |
EXP |
ginsenoside Rf affects the activity of KCNH2 protein |
CTD |
PMID:15842772 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
multiple interactions decreases expression |
ISO |
ginsenoside Rf binds to and results in decreased activity of PPARA protein; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased activity of PPARA protein]; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased expression of PPARA mRNA]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA] ginsenoside Rf results in decreased expression of PPARA mRNA |
CTD |
PMID:16297877 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
ginsenoside Rg2 results in increased expression of ABCC2 mRNA |
CTD |
PMID:23835644 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:28756148 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
APP |
amyloid beta precursor protein |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased expression of BAX protein] |
CTD |
PMID:28756148 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,550...26,171,128
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased expression of BAX protein] |
CTD |
PMID:28756148 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO |
ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein] |
CTD |
PMID:28756148 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BECN2 |
beclin 2 |
multiple interactions |
ISO EXP |
ginsenoside Rg2 inhibits the reaction [BECN2 protein binds to GPRASP1 protein] |
CTD |
PMID:27305347 |
|
NCBI chr 1:241,957,767...241,959,062
Ensembl chr 1:241,957,767...241,959,062
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein] |
CTD |
PMID:28756148 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
CRTC2 |
CREB regulated transcription coactivator 2 |
multiple interactions |
EXP |
[ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein |
CTD |
PMID:22062806 |
|
NCBI chr 1:153,947,675...153,958,612
Ensembl chr 1:153,947,669...153,958,615
|
|
G |
G6PC3 |
glucose-6-phosphatase catalytic subunit 3 |
decreases expression multiple interactions |
EXP |
ginsenoside Rg2 results in decreased expression of G6PC3 mRNA dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of G6PC3 mRNA] |
CTD |
PMID:22062806 |
|
NCBI chr17:44,070,673...44,076,344
Ensembl chr17:44,070,620...44,082,151
|
|
G |
GPRASP1 |
G protein-coupled receptor associated sorting protein 1 |
multiple interactions |
EXP ISO |
ginsenoside Rg2 inhibits the reaction [BECN2 protein binds to GPRASP1 protein] |
CTD |
PMID:27305347 |
|
NCBI chr X:102,651,483...102,659,083
Ensembl chr X:102,651,092...102,659,083
|
|
G |
GSK3B |
glycogen synthase kinase 3 beta |
increases phosphorylation multiple interactions |
EXP |
ginsenoside Rg2 results in increased phosphorylation of GSK3B protein [[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:22062806 |
|
NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions increases expression |
EXP |
bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:27305347 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
NR0B2 |
nuclear receptor subfamily 0 group B member 2 |
multiple interactions increases expression increases activity |
EXP |
[[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; [ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein |
CTD |
PMID:22062806 |
|
NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975
|
|
G |
PCK1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions decreases expression |
EXP |
dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of PCK1 mRNA] |
CTD |
PMID:22062806 |
|
NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
EXP |
dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:22062806 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions decreases expression |
EXP ISO |
bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in decreased expression of SQSTM1 protein] |
CTD |
PMID:27305347 |
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
G |
STK11 |
serine/threonine kinase 11 |
increases phosphorylation multiple interactions |
EXP |
ginsenoside Rg2 results in increased phosphorylation of STK11 protein dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of STK11 protein] |
CTD |
PMID:22062806 |
|
NCBI chr19:1,205,778...1,228,431
Ensembl chr19:1,177,558...1,228,431
|
|
|
G |
ACHE |
acetylcholinesterase (Cartwright blood group) |
multiple interactions |
ISO |
[2,2-bis(4-glycidyloxyphenyl)propane co-treated with Hesperidin] inhibits the reaction [[Sodium Fluoride results in increased abundance of Fluorides] which results in increased activity of ACHE protein]; Hesperidin inhibits the reaction [[Sodium Fluoride results in increased abundance of Fluorides] which results in increased activity of ACHE protein] |
CTD |
PMID:32627286 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
AFP |
alpha fetoprotein |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in increased expression of AFP protein]; Hesperidin inhibits the reaction [Diethylnitrosamine results in increased expression of AFP protein] |
CTD |
PMID:28935427 PMID:30779474 |
|
NCBI chr 4:73,436,221...73,456,174
Ensembl chr 4:73,431,138...73,456,174
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:30779474 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
ALB |
albumin |
multiple interactions increases expression |
ISO |
[Hesperidin co-treated with Doxorubicin] results in increased expression of ALB protein Hesperidin results in increased expression of ALB protein |
CTD |
PMID:29481770 |
|
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
|
|
G |
ATF6 |
activating transcription factor 6 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [abamectin results in increased expression of ATF6 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,298...161,977,574
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
[Hesperidin co-treated with Chlorpyrifos] results in increased expression of BAX mRNA; Hesperidin inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [[Streptozocin co-treated with Isoproterenol] affects the expression of BAX protein]]; Hesperidin inhibits the reaction [[Streptozocin co-treated with Isoproterenol] affects the expression of BAX protein]; Hesperidin inhibits the reaction [abamectin results in increased expression of BAX mRNA]; Hesperidin inhibits the reaction [abamectin results in increased expression of BAX protein]; Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in increased expression of BAX protein] Hesperidin results in increased expression of BAX mRNA Doxorubicin promotes the reaction [Hesperidin results in increased expression of BAX mRNA] |
CTD |
PMID:24954035 PMID:29481770 PMID:32050098 PMID:33908150 PMID:34748272 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions decreases expression |
ISO |
[Hesperidin co-treated with Chlorpyrifos] results in decreased expression of BCL2 mRNA; Hesperidin inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [[Streptozocin co-treated with Isoproterenol] affects the expression of BCL2 protein]]; Hesperidin inhibits the reaction [[Streptozocin co-treated with Isoproterenol] affects the expression of BCL2 protein]; Hesperidin inhibits the reaction [abamectin results in decreased expression of BCL2 mRNA]; Hesperidin inhibits the reaction [abamectin results in decreased expression of BCL2 protein]; Hesperidin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 mRNA]; Hesperidin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]; Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of BCL2 protein]; Hesperidin inhibits the reaction [Isoproterenol results in decreased expression of BCL2 protein] Hesperidin results in decreased expression of BCL2 mRNA Doxorubicin promotes the reaction [Hesperidin results in decreased expression of BCL2 mRNA] |
CTD |
PMID:22093918 PMID:24954035 PMID:29481770 PMID:30623541 PMID:32050098 PMID:33908150 PMID:34748272 More...
|
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BECN1 |
beclin 1 |
multiple interactions decreases expression |
ISO |
Hesperidin inhibits the reaction [abamectin results in increased expression of BECN1 protein]; Hesperidin inhibits the reaction [Chlorpyrifos results in increased expression of BECN1 protein] Hesperidin results in decreased expression of BECN1 protein |
CTD |
PMID:33908150 PMID:34748272 |
|
NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
|
|
G |
BMP2 |
bone morphogenetic protein 2 |
increases expression |
ISO |
Hesperidin results in increased expression of BMP2 mRNA |
CTD |
PMID:21820093 |
|
NCBI chr20:6,767,686...6,780,246
Ensembl chr20:6,767,686...6,780,246
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases expression increases activity |
ISO |
[Hesperidin co-treated with Chlorpyrifos] results in increased expression of CASP3 mRNA; Hesperidin inhibits the reaction [abamectin results in increased expression of CASP3 mRNA]; Hesperidin inhibits the reaction [abamectin results in increased expression of CASP3 protein]; Hesperidin inhibits the reaction [Acetaminophen results in increased expression of CASP3 mRNA]; Hesperidin inhibits the reaction [Acetaminophen results in increased expression of CASP3 protein]; Hesperidin inhibits the reaction [Isoproterenol results in increased expression of CASP3 protein]; Hesperidin inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; Hesperidin promotes the reaction [Diethylnitrosamine results in increased expression of CASP3 protein] [Hesperidin co-treated with Doxorubicin] results in increased activity of CASP3 protein; Doxorubicin promotes the reaction [Hesperidin results in increased expression of CASP3 mRNA] Hesperidin results in increased activity of CASP3 protein |
CTD |
PMID:22093918 PMID:29481770 PMID:30066062 PMID:30623541 PMID:30779474 PMID:33908150 PMID:34748272 More...
|
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Acetaminophen results in increased expression of CASP9 mRNA]; Hesperidin inhibits the reaction [Acetaminophen results in increased expression of CASP9 protein] |
CTD |
PMID:22093918 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions increases activity |
ISO |
Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [abamectin results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [Acetaminophen results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [Acetic Acid results in increased activity of CAT protein]; Hesperidin inhibits the reaction [Chlorpyrifos results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of CAT protein]; Hesperidin inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [Isoproterenol results in decreased expression of CAT protein]; Hesperidin inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] Hesperidin results in increased activity of CAT protein Hesperidin inhibits the reaction [Doxorubicin results in increased activity of CAT protein] |
CTD |
PMID:22093918 PMID:29481770 PMID:30066062 PMID:30098279 PMID:30623541 PMID:30779474 PMID:31095933 PMID:32050098 PMID:33908150 PMID:34748272 More...
|
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 protein]; Hesperidin inhibits the reaction [Ethanol results in increased expression of CCL3 protein] |
CTD |
PMID:30368987 PMID:30811821 |
|
NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
|
|
G |
CDK2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Diethylnitrosamine results in increased expression of CDK2 protein] |
CTD |
PMID:30779474 |
|
NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789
|
|
G |
CXCL1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein] |
CTD |
PMID:17400256 |
|
NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL8 protein]; Hesperidin inhibits the reaction [TNF protein co-treated with and results in increased expression of IL1B protein co-treated with and results in increased expression of CXCL8 protein] |
CTD |
PMID:17400256 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
EIF2AK3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [abamectin results in increased expression of EIF2AK3 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr 2:88,556,741...88,628,145
Ensembl chr 2:88,556,741...88,691,518
|
|
G |
ERN1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [abamectin results in increased expression of ERN1 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr17:64,039,142...64,130,144
Ensembl chr17:64,039,080...64,130,819
|
|
G |
FABP9 |
fatty acid binding protein 9 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in increased secretion of FABP9 protein] |
CTD |
PMID:32050098 |
|
NCBI chr 8:81,458,253...81,461,579
Ensembl chr 8:81,458,253...81,461,579
|
|
G |
FASN |
fatty acid synthase |
multiple interactions |
ISO |
Hesperidin affects the reaction [LEPR protein affects the activity of FASN protein] |
CTD |
PMID:16427799 |
|
NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294
|
|
G |
G6PD |
glucose-6-phosphate dehydrogenase |
decreases activity multiple interactions |
EXP ISO |
Hesperidin results in decreased activity of G6PD protein Hesperidin affects the reaction [LEPR protein affects the activity of G6PD protein] |
CTD |
PMID:16427799 PMID:25130191 |
|
NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572
|
|
G |
GCK |
glucokinase |
multiple interactions |
ISO |
Hesperidin affects the reaction [LEPR protein affects the expression of GCK mRNA] |
CTD |
PMID:16427799 |
|
NCBI chr 7:44,143,213...44,189,439
Ensembl chr 7:44,143,213...44,198,170
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions decreases activity |
ISO |
[Doxorubicin co-treated with Hesperidin] results in decreased activity of GPT protein Hesperidin inhibits the reaction [Chlorpyrifos results in increased activity of GPT protein]; Hesperidin inhibits the reaction [Diethylnitrosamine results in increased activity of GPT protein]; Hesperidin inhibits the reaction [sodium arsenite results in increased activity of GPT protein] Hesperidin results in decreased activity of GPT protein |
CTD |
PMID:29481770 PMID:30066062 PMID:30779474 PMID:33908150 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of GSR protein]; Hesperidin inhibits the reaction [Acetaminophen results in decreased activity of GSR protein] |
CTD |
PMID:22093918 PMID:30098279 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
HAVCR1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased secretion of HAVCR1 protein]; Hesperidin inhibits the reaction [Acetaminophen results in increased expression of HAVCR1 mRNA]; Hesperidin inhibits the reaction [Acetaminophen results in increased expression of HAVCR1 protein] |
CTD |
PMID:22093918 PMID:30098279 |
|
NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,029,413...157,059,119
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
Hesperidin affects the reaction [LEPR protein affects the activity of HMGCR protein] |
CTD |
PMID:16427799 |
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in decreased expression of HMOX1 protein]; Hesperidin inhibits the reaction [abamectin results in decreased expression of HMOX1 mRNA]; Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of HMOX1 protein] |
CTD |
PMID:28935427 PMID:32050098 PMID:34748272 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HSD3B1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of HSD3B1 protein] |
CTD |
PMID:32050098 |
|
NCBI chr 1:119,507,203...119,515,058
Ensembl chr 1:119,507,198...119,515,054
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [abamectin results in increased expression of HSPA5 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Glucose results in increased expression of ICAM1]; Hesperidin inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; Hesperidin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:17400256 PMID:22074828 |
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
EXP ISO |
Hesperidin inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; Hesperidin inhibits the reaction [IL1B protein results in increased expression of VCAM1 protein]; Hesperidin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Hesperidin inhibits the reaction [TNF protein co-treated with and results in increased expression of IL1B protein co-treated with and results in increased expression of CXCL8 protein] Hesperidin inhibits the reaction [abamectin results in increased expression of IL1B mRNA]; Hesperidin inhibits the reaction [Chlorpyrifos results in increased expression of IL1B protein]; Hesperidin inhibits the reaction [sodium arsenite results in increased expression of IL1B protein] Hesperidin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:17400256 PMID:30066062 PMID:33908150 PMID:34748272 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL4 |
interleukin 4 |
multiple interactions |
ISO |
Hesperidin promotes the reaction [Lipopolysaccharides results in increased expression of IL4 protein] |
CTD |
PMID:17400256 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
IL6 |
interleukin 6 |
multiple interactions decreases expression |
EXP ISO |
Hesperidin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Hesperidin results in decreased expression of IL6 protein [naringin co-treated with Hesperidin] results in decreased expression of IL6 protein; Hesperidin inhibits the reaction [abamectin results in increased expression of IL6 mRNA]; Hesperidin inhibits the reaction [Isoproterenol results in increased expression of IL6 protein]; Hesperidin inhibits the reaction [sodium arsenite results in increased expression of IL6 protein] |
CTD |
PMID:17400256 PMID:21820093 PMID:30066062 PMID:30623541 PMID:34748272 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
JAK2 |
Janus kinase 2 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [abamectin results in increased expression of JAK2 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr 9:4,984,390...5,129,948
Ensembl chr 9:4,984,390...5,129,948
|
|
G |
LEP |
leptin |
decreases expression multiple interactions |
ISO |
Hesperidin results in decreased expression of LEP protein [naringin co-treated with Hesperidin] results in decreased expression of LEP protein |
CTD |
PMID:21820093 |
|
NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629
|
|
G |
LEPR |
leptin receptor |
multiple interactions |
ISO |
Hesperidin affects the reaction [LEPR protein affects the abundance of Glucose]; Hesperidin affects the reaction [LEPR protein affects the activity of FASN protein]; Hesperidin affects the reaction [LEPR protein affects the activity of G6PD protein]; Hesperidin affects the reaction [LEPR protein affects the activity of HMGCR protein]; Hesperidin affects the reaction [LEPR protein affects the expression of GCK mRNA]; Hesperidin affects the reaction [LEPR protein affects the expression of PPARG protein]; Hesperidin affects the reaction [LEPR protein affects the expression of SLC2A2 protein]; Hesperidin affects the reaction [LEPR protein affects the expression of SLC2A4 protein] |
CTD |
PMID:16427799 |
|
NCBI chr 1:65,420,652...65,641,559
Ensembl chr 1:65,420,652...65,641,559
|
|
G |
MAP1LC3A |
microtubule associated protein 1 light chain 3 alpha |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [abamectin results in increased expression of MAP1LC3A mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr20:34,546,844...34,560,345
Ensembl chr20:34,546,854...34,560,345
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [abamectin results in increased expression of MAP1LC3B mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
MAPK14 |
mitogen-activated protein kinase 14 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [abamectin results in increased expression of MAPK14 mRNA]; Hesperidin inhibits the reaction [Chlorpyrifos results in increased expression of MAPK14 protein] |
CTD |
PMID:33908150 PMID:34748272 |
|
NCBI chr 6:36,027,808...36,124,214
Ensembl chr 6:36,027,677...36,111,236
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Acetaldehyde results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:19110045 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Hesperidin inhibits the reaction [Acetaldehyde results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:19110045 |
|
NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
|
|
G |
MIR126 |
microRNA 126 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of MIR126B mRNA] |
CTD |
PMID:32050098 |
|
NCBI chr 9:136,670,602...136,670,686
Ensembl chr 9:136,670,602...136,670,686
|
|
G |
MIR181A2 |
microRNA 181a-2 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in increased expression of MIR181A2 mRNA] |
CTD |
PMID:32050098 |
|
NCBI chr 9:124,692,442...124,692,551
Ensembl chr 9:124,692,442...124,692,551
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions decreases secretion |
EXP |
Hesperidin inhibits the reaction [Acetaldehyde results in increased expression of and results in increased activity of MMP9 protein]; Hesperidin inhibits the reaction [Acetaldehyde results in increased expression of MMP9 mRNA]; Hesperidin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA] Hesperidin results in decreased secretion of MMP9 protein |
CTD |
PMID:19110045 PMID:20138977 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MPO |
myeloperoxidase |
decreases activity multiple interactions |
ISO |
Hesperidin results in decreased activity of MPO protein Hesperidin inhibits the reaction [Acetic Acid results in increased activity of MPO protein] |
CTD |
PMID:31095933 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in decreased expression of NFE2L2 mRNA]; Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in decreased expression of NFE2L2 protein]; Hesperidin inhibits the reaction [abamectin results in decreased expression of NFE2L2 mRNA]; Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of NFE2L2 protein] |
CTD |
PMID:28935427 PMID:32050098 PMID:34748272 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,227,595...177,392,697
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [abamectin results in increased expression of NFKB1 mRNA]; Hesperidin inhibits the reaction [Acetaminophen results in increased expression of NFKB1 mRNA] |
CTD |
PMID:22093918 PMID:34748272 |
|
NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,331...102,617,302
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] Hesperidin inhibits the reaction [Acetaminophen results in increased expression of NOS2 mRNA]; Hesperidin inhibits the reaction [Acetaminophen results in increased expression of NOS2 protein]; Hesperidin inhibits the reaction [Chlorpyrifos results in increased expression of NOS2 protein] |
CTD |
PMID:12512693 PMID:22093918 PMID:33908150 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[Hesperidin co-treated with Chlorpyrifos] results in increased expression of PARP1 mRNA; [Hesperidin co-treated with Chlorpyrifos] results in increased expression of PARP1 protein; Hesperidin inhibits the reaction [Ethanol results in increased activity of PARP1 protein] |
CTD |
PMID:30368987 PMID:33908150 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PCNA |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in increased expression of PCNA protein] |
CTD |
PMID:28935427 |
|
NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
|
|
G |
PIK3R1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Diethylnitrosamine results in increased expression of PIK3R1 protein] |
CTD |
PMID:30779474 |
|
NCBI chr 5:68,215,756...68,301,821
Ensembl chr 5:68,215,756...68,301,821
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [2-chloro-5-nitrobenzanilide promotes the reaction [[Streptozocin co-treated with Isoproterenol] affects the expression of PPARG protein]]; Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in decreased expression of PPARG mRNA]; Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in decreased expression of PPARG protein]; Hesperidin inhibits the reaction [[Streptozocin co-treated with Isoproterenol] affects the expression of PPARG protein]; Hesperidin inhibits the reaction [Isoproterenol results in decreased expression of PPARG protein] Hesperidin affects the reaction [LEPR protein affects the expression of PPARG protein] |
CTD |
PMID:16427799 PMID:24954035 PMID:28935427 PMID:30623541 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Dextran Sulfate results in decreased expression of PPARGC1A protein]; Hesperidin inhibits the reaction [Ethanol results in decreased expression of PPARGC1A protein] |
CTD |
PMID:30368987 PMID:30811821 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO EXP |
Hesperidin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein]; Hesperidin inhibits the reaction [Chlorpyrifos results in increased expression of PTGS2 protein] Hesperidin inhibits the reaction [Acetaldehyde results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16101151 PMID:19110045 PMID:30098279 PMID:33908150 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Isoproterenol results in increased expression of RELA protein] |
CTD |
PMID:30623541 |
|
NCBI chr11:65,653,601...65,662,916
Ensembl chr11:65,653,599...65,663,090
|
|
G |
SGPP2 |
sphingosine-1-phosphate phosphatase 2 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of SGPP2 mRNA] |
CTD |
PMID:30811821 |
|
NCBI chr 2:222,423,988...222,562,621
Ensembl chr 2:222,424,543...222,562,621
|
|
G |
SIRT1 |
sirtuin 1 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SIRT1 mRNA]; Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SIRT1 protein] |
CTD |
PMID:32050098 |
|
NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390
|
|
G |
SLC2A2 |
solute carrier family 2 member 2 |
multiple interactions |
ISO |
Hesperidin affects the reaction [LEPR protein affects the expression of SLC2A2 protein] |
CTD |
PMID:16427799 |
|
NCBI chr 3:170,996,347...171,026,720
Ensembl chr 3:170,996,347...171,026,743
|
|
G |
SLC2A4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
Hesperidin affects the reaction [LEPR protein affects the expression of SLC2A4 protein] |
CTD |
PMID:16427799 |
|
NCBI chr17:7,281,718...7,288,257
Ensembl chr17:7,281,718...7,288,257
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SOD2 mRNA]; Hesperidin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SOD2 protein] |
CTD |
PMID:32050098 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SPHK1 |
sphingosine kinase 1 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of SPHK1 protein] |
CTD |
PMID:30811821 |
|
NCBI chr17:76,383,204...76,387,855
Ensembl chr17:76,376,584...76,387,860
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [abamectin results in increased expression of STAT3 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,540
|
|
G |
TFEB |
transcription factor EB |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Ethanol results in decreased expression of TFEB mRNA] |
CTD |
PMID:30368987 |
|
NCBI chr 6:41,683,978...41,736,223
Ensembl chr 6:41,683,978...41,736,259
|
|
G |
TNC |
tenascin C |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [Ethanol results in increased expression of TNC protein] |
CTD |
PMID:30368987 |
|
NCBI chr 9:115,019,575...115,118,157
Ensembl chr 9:115,019,575...115,118,257
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Hesperidin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Hesperidin inhibits the reaction [TNF protein co-treated with and results in increased expression of IL1B protein co-treated with and results in increased expression of CXCL8 protein]; Hesperidin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Hesperidin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] Hesperidin inhibits the reaction [[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in increased expression of TNF protein]; Hesperidin inhibits the reaction [abamectin results in increased expression of TNF mRNA]; Hesperidin inhibits the reaction [Chlorpyrifos results in increased expression of TNF protein]; Hesperidin inhibits the reaction [Isoproterenol results in increased expression of TNF protein]; Hesperidin inhibits the reaction [sodium arsenite results in increased expression of TNF protein] Hesperidin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:17400256 PMID:28935427 PMID:30066062 PMID:30623541 PMID:33908150 PMID:34748272 More...
|
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFRSF25 |
TNF receptor superfamily member 25 |
increases expression |
EXP |
Hesperidin results in increased expression of TNFRSF25 mRNA |
CTD |
PMID:24633329 |
|
NCBI chr 1:6,460,786...6,466,173
Ensembl chr 1:6,460,786...6,466,175
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
ISO |
Hesperidin inhibits the reaction [sodium arsenite results in increased expression of TP53 protein] |
CTD |
PMID:30066062 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
|
|
G |
TRADD |
TNFRSF1A associated via death domain |
increases expression |
EXP |
Hesperidin results in increased expression of TRADD mRNA |
CTD |
PMID:24633329 |
|
NCBI chr16:67,154,185...67,159,909
Ensembl chr16:67,154,185...67,159,909
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases expression |
EXP |
Hesperidin inhibits the reaction [IL1B protein results in increased expression of VCAM1 protein]; Hesperidin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] Hesperidin results in decreased expression of VCAM1 |
CTD |
PMID:17400256 PMID:30991044 |
|
NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[Hesperidin co-treated with Chlorpyrifos] results in increased expression of VEGFA protein |
CTD |
PMID:33908150 |
|
NCBI chr 6:43,770,209...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
|
G |
ACLY |
ATP citrate lyase |
affects response to substance |
EXP |
ACLY protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr17:41,866,917...41,930,545
Ensembl chr17:41,866,917...41,930,542
|
|
G |
ARF1 |
ADP ribosylation factor 1 |
affects response to substance |
EXP |
ARF1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 1:228,082,708...228,099,212
Ensembl chr 1:228,082,660...228,099,212
|
|
G |
ATP5F1B |
ATP synthase F1 subunit beta |
affects response to substance |
EXP |
ATP5B protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr12:56,638,175...56,645,984
Ensembl chr12:56,638,175...56,645,984
|
|
G |
ATP5PB |
ATP synthase peripheral stalk-membrane subunit b |
affects response to substance |
EXP |
ATP5F1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 1:111,449,464...111,462,773
Ensembl chr 1:111,448,864...111,462,773
|
|
G |
ATP5PD |
ATP synthase peripheral stalk subunit d |
affects response to substance |
EXP |
ATP5H protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr17:75,038,863...75,046,969
Ensembl chr17:75,038,863...75,046,985
|
|
G |
ATP5PO |
ATP synthase peripheral stalk subunit OSCP |
affects response to substance |
EXP |
ATP5O protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr21:33,903,453...33,915,804
Ensembl chr21:33,903,453...33,915,814
|
|
G |
ATRX |
ATRX chromatin remodeler |
affects response to substance |
EXP |
ATRX protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr X:77,504,880...77,786,216
Ensembl chr X:77,504,880...77,786,233
|
|
G |
CLPP |
caseinolytic mitochondrial matrix peptidase proteolytic subunit |
affects response to substance |
EXP |
CLPP protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr19:6,361,531...6,370,242
Ensembl chr19:6,361,531...6,370,242
|
|
G |
CLPX |
caseinolytic mitochondrial matrix peptidase chaperone subunit X |
affects response to substance |
EXP |
CLPX protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr15:65,148,219...65,185,342
Ensembl chr15:65,148,219...65,185,342
|
|
G |
CR1 |
complement C3b/C4b receptor 1 (Knops blood group) |
decreases expression multiple interactions |
EXP |
Josamycin results in decreased expression of CR1 protein Ribomunyl inhibits the reaction [Josamycin results in decreased expression of CR1 protein] |
CTD |
PMID:8096833 |
|
NCBI chr 1:207,496,157...207,641,765
Ensembl chr 1:207,496,147...207,641,765
|
|
G |
CS |
citrate synthase |
affects response to substance |
EXP |
CS protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr12:56,271,699...56,300,330
Ensembl chr12:56,271,699...56,300,391
|
|
G |
DAZAP1 |
DAZ associated protein 1 |
affects response to substance |
EXP |
DAZAP1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr19:1,407,586...1,435,684
Ensembl chr19:1,407,569...1,435,687
|
|
G |
EIF2AK1 |
eukaryotic translation initiation factor 2 alpha kinase 1 |
affects response to substance |
EXP |
EIF2AK1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 7:6,022,247...6,059,175
Ensembl chr 7:6,022,247...6,059,175
|
|
G |
EIF4G1 |
eukaryotic translation initiation factor 4 gamma 1 |
affects response to substance |
EXP |
EIF4G1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 3:184,314,606...184,335,358
Ensembl chr 3:184,314,495...184,335,358
|
|
G |
FBXO11 |
F-box protein 11 |
affects response to substance |
EXP |
FBXO11 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 2:47,806,920...47,906,498
Ensembl chr 2:47,789,316...47,906,498
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Josamycin results in increased expression of FOS mRNA; Josamycin results in increased expression of FOS protein |
CTD |
PMID:32454074 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
GADD45A |
growth arrest and DNA damage inducible alpha |
affects response to substance |
EXP |
GADD45A protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334
|
|
G |
GFM2 |
GTP dependent ribosome recycling factor mitochondrial 2 |
affects response to substance |
EXP |
GFM2 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 5:74,721,206...74,767,117
Ensembl chr 5:74,721,206...74,767,147
|
|
G |
GPI |
glucose-6-phosphate isomerase |
decreases response to substance |
EXP |
GPI protein results in decreased susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr19:34,359,718...34,402,413
Ensembl chr19:34,359,480...34,402,413
|
|
G |
HK2 |
hexokinase 2 |
decreases response to substance |
EXP |
HK2 protein results in decreased susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 2:74,834,127...74,893,359
Ensembl chr 2:74,834,127...74,893,359
|
|
G |
HNRNPA1 |
heterogeneous nuclear ribonucleoprotein A1 |
affects response to substance |
EXP |
HNRNPA1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr12:54,280,726...54,287,087
Ensembl chr12:54,280,193...54,287,088
|
|
G |
ITGB2 |
integrin subunit beta 2 |
multiple interactions decreases expression |
EXP |
Ribomunyl inhibits the reaction [Josamycin results in decreased expression of ITGB2 protein] |
CTD |
PMID:8096833 |
|
NCBI chr21:44,885,953...44,928,815
Ensembl chr21:44,885,953...44,931,989
|
|
G |
MAP2K3 |
mitogen-activated protein kinase kinase 3 |
affects response to substance |
EXP |
MAP2K3 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr17:21,284,711...21,315,240
Ensembl chr17:21,284,672...21,315,232
|
|
G |
MAP3K4 |
mitogen-activated protein kinase kinase kinase 4 |
decreases response to substance |
EXP |
MAP3K4 protein results in decreased susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 6:160,991,769...161,117,380
Ensembl chr 6:160,991,727...161,117,385
|
|
G |
ME2 |
malic enzyme 2 |
affects response to substance |
EXP |
ME2 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr18:50,879,118...50,954,257
Ensembl chr18:50,879,080...50,954,257
|
|
G |
MT-CO2 |
mitochondrially encoded cytochrome c oxidase II |
decreases expression |
EXP |
Josamycin results in decreased expression of COX2 protein |
CTD |
PMID:31915244 |
|
NCBI chr MT:7,586...8,269
Ensembl chr MT:7,586...8,269
|
|
G |
MTFMT |
mitochondrial methionyl-tRNA formyltransferase |
decreases response to substance |
EXP |
MTFMT protein results in decreased susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr15:65,001,512...65,029,639
Ensembl chr15:65,001,512...65,029,639
|
|
G |
MTIF2 |
mitochondrial translational initiation factor 2 |
decreases response to substance |
EXP |
MTIF2 protein results in decreased susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 2:55,236,595...55,269,248
Ensembl chr 2:55,236,595...55,269,347
|
|
G |
MTIF3 |
mitochondrial translational initiation factor 3 |
decreases response to substance |
EXP |
MTIF3 protein results in decreased susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr13:27,435,643...27,450,564
Ensembl chr13:27,435,643...27,450,591
|
|
G |
NDUFB8 |
NADH:ubiquinone oxidoreductase subunit B8 |
affects response to substance |
EXP |
NDUFB8 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr10:100,523,729...100,529,923
Ensembl chr10:100,523,740...100,530,000
|
|
G |
NPM1 |
nucleophosmin 1 |
affects response to substance |
EXP |
NPM1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 5:171,387,116...171,410,900
Ensembl chr 5:171,387,116...171,411,810
|
|
G |
PCM1 |
pericentriolar material 1 |
affects response to substance |
EXP |
PCM1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 8:17,922,988...18,029,948
Ensembl chr 8:17,922,968...18,029,948
|
|
G |
PFKP |
phosphofructokinase, platelet |
decreases response to substance |
EXP |
PFKP protein results in decreased susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr10:3,067,548...3,136,805
Ensembl chr10:3,066,333...3,137,718
|
|
G |
PPP1R15B |
protein phosphatase 1 regulatory subunit 15B |
affects response to substance |
EXP |
PPP1R15B protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 1:204,395,826...204,411,817
Ensembl chr 1:204,396,492...204,411,887
|
|
G |
PPP2R2A |
protein phosphatase 2 regulatory subunit Balpha |
affects response to substance |
EXP |
PPP2R2A protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 8:26,291,508...26,372,680
Ensembl chr 8:26,291,508...26,372,680
|
|
G |
PRKDC |
protein kinase, DNA-activated, catalytic subunit |
affects response to substance |
EXP |
PRKDC protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 8:47,773,111...47,960,136
Ensembl chr 8:47,773,111...47,960,178
|
|
G |
RTRAF |
RNA transcription, translation and transport factor |
affects response to substance |
EXP |
RTRAF protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr14:51,989,546...52,010,694
Ensembl chr14:51,989,514...52,010,694
|
|
G |
SLC16A1 |
solute carrier family 16 member 1 |
affects response to substance |
EXP |
SLC16A1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 1:112,911,847...112,956,196
Ensembl chr 1:112,911,847...112,957,593
|
|
G |
SMG1 |
SMG1 nonsense mediated mRNA decay associated PI3K related kinase |
affects response to substance |
EXP |
SMG1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr16:18,804,860...18,926,408
Ensembl chr16:18,804,860...18,926,408
|
|
G |
SMG7 |
SMG7 nonsense mediated mRNA decay factor |
affects response to substance |
EXP |
SMG7 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 1:183,472,499...183,554,191
Ensembl chr 1:183,472,216...183,598,246
|
|
G |
STRAP |
serine/threonine kinase receptor associated protein |
affects response to substance |
EXP |
STRAP protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr12:15,882,387...15,903,478
Ensembl chr12:15,882,387...15,903,478
|
|
G |
TAF3 |
TATA-box binding protein associated factor 3 |
affects response to substance |
EXP |
TAF3 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr10:7,818,505...8,016,631
Ensembl chr10:7,818,497...8,016,631
|
|
G |
TAF4 |
TATA-box binding protein associated factor 4 |
affects response to substance |
EXP |
TAF4 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr20:61,974,798...62,065,881
Ensembl chr20:61,953,469...62,065,881
|
|
G |
TPX2 |
TPX2 microtubule nucleation factor |
affects response to substance |
EXP |
TPX2 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr20:31,739,290...31,801,800
Ensembl chr20:31,739,271...31,801,805
|
|
G |
TRIAP1 |
TP53 regulated inhibitor of apoptosis 1 |
affects response to substance |
EXP |
TRIAP1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr12:120,443,964...120,446,384
Ensembl chr12:120,443,964...120,446,384
|
|
G |
UBAP2L |
ubiquitin associated protein 2 like |
affects response to substance |
EXP |
UBAP2L protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 1:154,220,172...154,271,510
Ensembl chr 1:154,220,179...154,271,510
|
|
G |
VDAC1 |
voltage dependent anion channel 1 |
affects response to substance |
EXP |
VDAC1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 5:133,971,871...134,114,540
Ensembl chr 5:133,971,871...134,004,975
|
|
G |
VDAC2 |
voltage dependent anion channel 2 |
affects response to substance |
EXP |
VDAC2 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr10:75,210,170...75,231,448
Ensembl chr10:75,210,154...75,231,448
|
|
|
G |
HMGB1 |
high mobility group box 1 |
multiple interactions decreases response to substance |
EXP |
kaempferol 3-O-sophoroside inhibits the reaction [HMGB1 protein results in increased expression of ICAM1 protein]; kaempferol 3-O-sophoroside inhibits the reaction [HMGB1 protein results in increased expression of SELE protein]; kaempferol 3-O-sophoroside inhibits the reaction [HMGB1 protein results in increased expression of TLR2 protein]; kaempferol 3-O-sophoroside inhibits the reaction [HMGB1 protein results in increased expression of TLR4 protein]; kaempferol 3-O-sophoroside inhibits the reaction [HMGB1 protein results in increased expression of VCAM1 protein]; kaempferol 3-O-sophoroside inhibits the reaction [Lipopolysaccharides results in increased secretion of HMGB1 protein] kaempferol 3-O-sophoroside results in decreased susceptibility to HMGB1 protein |
CTD |
PMID:22178603 |
|
NCBI chr13:30,456,704...30,617,597
Ensembl chr13:30,456,704...30,617,597
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
kaempferol 3-O-sophoroside inhibits the reaction [HMGB1 protein results in increased expression of ICAM1 protein] |
CTD |
PMID:22178603 |
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
SELE |
selectin E |
multiple interactions |
EXP |
kaempferol 3-O-sophoroside inhibits the reaction [HMGB1 protein results in increased expression of SELE protein] |
CTD |
PMID:22178603 |
|
NCBI chr 1:169,722,640...169,734,079
Ensembl chr 1:169,722,640...169,764,705
|
|
G |
TLR2 |
toll like receptor 2 |
multiple interactions |
EXP |
kaempferol 3-O-sophoroside inhibits the reaction [HMGB1 protein results in increased expression of TLR2 protein] |
CTD |
PMID:22178603 |
|
NCBI chr 4:153,684,280...153,710,637
Ensembl chr 4:153,684,070...153,706,260
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions |
EXP |
kaempferol 3-O-sophoroside inhibits the reaction [HMGB1 protein results in increased expression of TLR4 protein] |
CTD |
PMID:22178603 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
kaempferol 3-O-sophoroside inhibits the reaction [HMGB1 protein results in increased expression of VCAM1 protein] |
CTD |
PMID:22178603 |
|
NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045
|
|
|
G |
CAT |
catalase |
decreases activity |
ISO |
Lactose results in decreased activity of CAT protein |
CTD |
PMID:2539851 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
LGALS3 |
galectin 3 |
affects binding |
EXP |
Lactose binds to LGALS3 protein |
CTD |
PMID:17385862 |
|
NCBI chr14:55,129,252...55,145,430
Ensembl chr14:55,124,110...55,145,423
|
|
G |
SOD1 |
superoxide dismutase 1 |
decreases activity |
ISO |
Lactose results in decreased activity of SOD1 protein |
CTD |
PMID:2539851 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
|
G |
BAG3 |
BAG cochaperone 3 |
increases expression |
ISO |
Lactulose results in increased expression of BAG3 mRNA |
CTD |
PMID:30335591 |
|
NCBI chr10:119,651,380...119,677,819
Ensembl chr10:119,651,380...119,677,819
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
Lactulose inhibits the reaction [Methamphetamine results in increased expression of CASP3 protein modified form] |
CTD |
PMID:30450033 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression |
ISO |
Lactulose results in increased expression of HMOX1 mRNA |
CTD |
PMID:30450033 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HSPB8 |
heat shock protein family B (small) member 8 |
increases expression |
ISO |
Lactulose results in increased expression of HSPB8 mRNA |
CTD |
PMID:30335591 |
|
NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
Lactulose inhibits the reaction [Methamphetamine results in increased expression of IL1B protein] |
CTD |
PMID:30450033 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
Lactulose inhibits the reaction [Methamphetamine results in increased expression of IL6 protein] |
CTD |
PMID:30450033 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
increases expression |
ISO |
Lactulose results in increased expression of MAP1LC3B mRNA |
CTD |
PMID:30335591 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
MYD88 |
MYD88 innate immune signal transduction adaptor |
multiple interactions |
ISO |
Lactulose inhibits the reaction [Methamphetamine results in increased expression of MYD88 protein] |
CTD |
PMID:30450033 |
|
NCBI chr 3:38,138,661...38,143,022
Ensembl chr 3:38,138,478...38,143,022
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
Lactulose promotes the reaction [Methamphetamine results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:30450033 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,227,595...177,392,697
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Lactulose inhibits the reaction [Methamphetamine results in increased expression of PARP1 protein modified form] |
CTD |
PMID:30450033 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Lactulose inhibits the reaction [Methamphetamine results in increased expression of RELA protein] |
CTD |
PMID:30450033 |
|
NCBI chr11:65,653,601...65,662,916
Ensembl chr11:65,653,599...65,663,090
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions increases expression |
ISO |
Lactulose promotes the reaction [Methamphetamine results in increased expression of SQSTM1 mRNA] Lactulose results in increased expression of SQSTM1 mRNA |
CTD |
PMID:30335591 PMID:30450033 |
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
G |
TFEB |
transcription factor EB |
multiple interactions affects localization |
ISO |
Cyclosporine inhibits the reaction [Lactulose affects the localization of TFEB protein] |
CTD |
PMID:30335591 |
|
NCBI chr 6:41,683,978...41,736,223
Ensembl chr 6:41,683,978...41,736,259
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions |
ISO |
Lactulose inhibits the reaction [Methamphetamine results in increased expression of TLR4 protein] |
CTD |
PMID:30450033 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Lactulose inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] Lactulose inhibits the reaction [Methamphetamine results in increased expression of TNF protein] |
CTD |
PMID:2311978 PMID:30450033 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TRAF6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
Lactulose inhibits the reaction [Methamphetamine results in increased expression of TRAF6 protein] |
CTD |
PMID:30450033 |
|
NCBI chr11:36,483,769...36,510,272
Ensembl chr11:36,483,769...36,510,272
|
|
G |
ZKSCAN3 |
zinc finger with KRAB and SCAN domains 3 |
increases expression |
ISO |
Lactulose results in increased expression of ZKSCAN3 mRNA |
CTD |
PMID:30335591 |
|
NCBI chr 6:28,349,878...28,369,172
Ensembl chr 6:28,349,947...28,369,172
|
|
|
G |
MGAM |
maltase-glucoamylase |
increases metabolic processing multiple interactions |
ISO |
MGAM protein results in increased metabolism of Maltose [MGAM protein results in increased metabolism of Maltose] which results in increased abundance of Glucose |
CTD |
PMID:17585022 |
|
NCBI chr 7:141,986,518...142,106,747
Ensembl chr 7:141,907,813...142,106,747
|
|
G |
SLC2A2 |
solute carrier family 2 member 2 |
multiple interactions |
EXP |
Maltose inhibits the reaction [SLC2A2 protein results in increased transport of Deoxyglucose]; Maltose inhibits the reaction [SLC2A2 protein results in increased transport of Fructose] |
CTD |
PMID:8457197 |
|
NCBI chr 3:170,996,347...171,026,720
Ensembl chr 3:170,996,347...171,026,743
|
|
G |
SLC2A3 |
solute carrier family 2 member 3 |
multiple interactions |
EXP |
Maltose inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose]; Maltose inhibits the reaction [SLC2A3 protein results in increased transport of Galactose] |
CTD |
PMID:8457197 |
|
NCBI chr12:7,919,230...7,936,187
Ensembl chr12:7,919,230...7,936,187
|
|
|
G |
BAG3 |
BAG cochaperone 3 |
increases expression |
ISO |
Melibiose results in increased expression of BAG3 mRNA |
CTD |
PMID:30335591 |
|
NCBI chr10:119,651,380...119,677,819
Ensembl chr10:119,651,380...119,677,819
|
|
G |
HSPB8 |
heat shock protein family B (small) member 8 |
increases expression |
ISO |
Melibiose results in increased expression of HSPB8 mRNA |
CTD |
PMID:30335591 |
|
NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
increases expression |
ISO |
Melibiose results in increased expression of MAP1LC3B mRNA |
CTD |
PMID:30335591 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
SQSTM1 |
sequestosome 1 |
increases expression |
ISO |
Melibiose results in increased expression of SQSTM1 mRNA |
CTD |
PMID:30335591 |
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
G |
TFEB |
transcription factor EB |
multiple interactions affects localization |
ISO |
Cyclosporine inhibits the reaction [Melibiose affects the localization of TFEB protein] |
CTD |
PMID:30335591 |
|
NCBI chr 6:41,683,978...41,736,223
Ensembl chr 6:41,683,978...41,736,259
|
|
G |
ZKSCAN3 |
zinc finger with KRAB and SCAN domains 3 |
increases expression |
ISO |
Melibiose results in increased expression of ZKSCAN3 mRNA |
CTD |
PMID:30335591 |
|
NCBI chr 6:28,349,878...28,369,172
Ensembl chr 6:28,349,947...28,369,172
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions |
EXP |
naringin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]] |
CTD |
PMID:34217736 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ACACA |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[naringin co-treated with Dietary Fats] results in decreased expression of ACACA mRNA |
CTD |
PMID:22198281 |
|
NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836
|
|
G |
ACE |
angiotensin I converting enzyme |
multiple interactions |
ISO |
naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased activity of ACE protein]; naringin inhibits the reaction [bisphenol A promotes the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ACE protein]]; naringin inhibits the reaction [bisphenol A results in increased activity of ACE protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester promotes the reaction [bisphenol A results in increased activity of ACE protein]]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ACE protein] |
CTD |
PMID:32172062 PMID:32810514 |
|
NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380
|
|
G |
ACHE |
acetylcholinesterase (Cartwright blood group) |
multiple interactions |
ISO |
[NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in increased expression of ACHE protein; [NG-Nitroarginine Methyl Ester co-treated with naringin] results in increased expression of ACHE protein; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased activity of ACHE protein]; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of ACHE protein]; naringin inhibits the reaction [bisphenol A results in increased activity of ACHE protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ACHE protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of ACHE protein] |
CTD |
PMID:32172062 PMID:32428650 PMID:32810514 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
ACOX1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr17:75,941,507...75,979,166
Ensembl chr17:75,941,507...75,979,177
|
|
G |
ACP5 |
acid phosphatase 5, tartrate resistant |
multiple interactions decreases expression |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ACP5 mRNA]; naringin inhibits the reaction [Polymethyl Methacrylate analog results in increased expression of and results in increased activity of ACP5 protein] naringin results in decreased expression of ACP5 mRNA |
CTD |
PMID:21835177 PMID:24376342 |
|
NCBI chr19:11,574,660...11,578,975
Ensembl chr19:11,574,653...11,579,993
|
|
G |
ADA |
adenosine deaminase |
multiple interactions |
ISO |
naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased activity of ADA protein]; naringin inhibits the reaction [bisphenol A results in increased activity of ADA protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ADA protein] |
CTD |
PMID:32172062 PMID:32428650 PMID:32810514 |
|
NCBI chr20:44,619,522...44,651,699
Ensembl chr20:44,584,896...44,652,252
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] |
CTD |
PMID:22198281 |
|
NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463
|
|
G |
AGT |
angiotensinogen |
multiple interactions |
EXP |
naringin inhibits the reaction [AGT protein results in increased expression of CYP11B2 mRNA]; naringin inhibits the reaction [AGT protein results in increased secretion of Aldosterone] |
CTD |
PMID:22798349 |
|
NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of AKT1 protein]; naringin inhibits the reaction [Methylprednisolone results in decreased phosphorylation of AKT1 protein]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; plerixafor inhibits the reaction [naringin results in increased phosphorylation of AKT1 protein] naringin inhibits the reaction [Dexamethasone results in decreased phosphorylation of AKT1 protein]; naringin inhibits the reaction [Dexamethasone results in increased expression of AKT1 mRNA] |
CTD |
PMID:19810018 PMID:25773745 PMID:29510123 PMID:30878453 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
ANGPT1 |
angiopoietin 1 |
affects expression |
ISO |
naringin affects the expression of ANGPT1 mRNA |
CTD |
PMID:24880026 |
|
NCBI chr 8:107,249,482...107,497,918
Ensembl chr 8:107,249,482...107,498,055
|
|
G |
AQP1 |
aquaporin 1 (Colton blood group) |
multiple interactions |
ISO |
naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP1 mRNA]; naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP1 protein] |
CTD |
PMID:31301536 |
|
NCBI chr 7:30,911,853...30,925,516
Ensembl chr 7:30,911,853...30,925,517
|
|
G |
AQP5 |
aquaporin 5 |
multiple interactions |
ISO |
naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP5 mRNA]; naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP5 protein] |
CTD |
PMID:31301536 |
|
NCBI chr12:49,961,872...49,965,682
Ensembl chr12:49,961,872...49,965,682
|
|
G |
ATP6V0D2 |
ATPase H+ transporting V0 subunit d2 |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ATP6V0D2 mRNA] |
CTD |
PMID:21835177 |
|
NCBI chr 8:86,098,910...86,154,225
Ensembl chr 8:85,987,323...86,154,225
|
|
G |
BAD |
BCL2 associated agonist of cell death |
multiple interactions |
ISO |
naringin inhibits the reaction [3-nitropropionic acid results in increased expression of BAD mRNA] naringin inhibits the reaction [Dexamethasone results in increased phosphorylation of BAD protein] |
CTD |
PMID:21945202 PMID:30878453 |
|
NCBI chr11:64,269,828...64,284,704
Ensembl chr11:64,269,830...64,284,704
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP ISO |
naringin results in increased expression of BAX mRNA naringin inhibits the reaction [Dexamethasone results in increased expression of BAX protein] naringin inhibits the reaction [Cadmium Chloride results in increased expression of BAX protein] [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of BAX mRNA]; naringin inhibits the reaction [3-nitropropionic acid results in increased expression of BAX mRNA]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of BAX mRNA] |
CTD |
PMID:21945202 PMID:22847135 PMID:28422390 PMID:30130594 PMID:30878453 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCHE |
butyrylcholinesterase |
multiple interactions |
ISO |
naringin inhibits the reaction [[bisphenol A co-treated with NG-Nitroarginine Methyl Ester] results in increased activity of BCHE protein]; naringin inhibits the reaction [bisphenol A results in increased activity of BCHE protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of BCHE protein] |
CTD |
PMID:32172062 PMID:32810514 |
|
NCBI chr 3:165,772,904...165,837,423
Ensembl chr 3:165,772,904...165,837,462
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO EXP |
[naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in decreased expression of BCL2 mRNA]; naringin inhibits the reaction [3-nitropropionic acid results in decreased expression of BCL2 mRNA]; naringin inhibits the reaction [Quinolinic Acid results in decreased expression of BCL2 mRNA] naringin inhibits the reaction [Dexamethasone results in decreased expression of BCL2 protein] naringin inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein] |
CTD |
PMID:21945202 PMID:28422390 PMID:30130594 PMID:30878453 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BGLAP |
bone gamma-carboxyglutamate protein |
increases expression increases secretion multiple interactions |
EXP ISO |
naringin results in increased expression of BGLAP mRNA; naringin results in increased expression of BGLAP protein naringin results in increased secretion of BGLAP protein fulvestrant inhibits the reaction [naringin results in increased secretion of BGLAP protein] |
CTD |
PMID:18495116 PMID:21741227 PMID:23596885 |
|
NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317
|
|
G |
BMP2 |
bone morphogenetic protein 2 |
multiple interactions decreases expression increases secretion increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin promotes the reaction [FOS protein binds to BMP2 promoter]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin promotes the reaction [JUN protein binds to BMP2 promoter]]; FOS protein affects the reaction [naringin results in increased expression of BMP2 mRNA]; FOS protein affects the reaction [naringin results in increased expression of BMP2 protein]; JUN protein affects the reaction [naringin results in increased expression of BMP2 mRNA]; JUN protein affects the reaction [naringin results in increased expression of BMP2 protein]; naringin promotes the reaction [FOS protein binds to BMP2 promoter]; naringin promotes the reaction [JUN protein binds to BMP2 promoter] naringin results in decreased expression of BMP2 mRNA fulvestrant inhibits the reaction [naringin results in increased secretion of BMP2 protein] naringin results in increased expression of BMP2 mRNA; naringin results in increased expression of BMP2 protein |
CTD |
PMID:18495116 PMID:21820093 PMID:23596885 |
|
NCBI chr20:6,767,686...6,780,246
Ensembl chr20:6,767,686...6,780,246
|
|
G |
BMP3 |
bone morphogenetic protein 3 |
decreases expression |
ISO |
naringin results in decreased expression of BMP3 mRNA |
CTD |
PMID:18495116 |
|
NCBI chr 4:81,030,708...81,057,627
Ensembl chr 4:81,030,708...81,057,627
|
|
G |
BMP4 |
bone morphogenetic protein 4 |
increases expression |
EXP |
naringin results in increased expression of BMP4 mRNA |
CTD |
PMID:24915843 |
|
NCBI chr14:53,949,736...53,956,891
Ensembl chr14:53,949,736...53,958,761
|
|
G |
CALCR |
calcitonin receptor |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CALCR mRNA] |
CTD |
PMID:21835177 |
|
NCBI chr 7:93,424,486...93,574,724
Ensembl chr 7:93,424,486...93,574,730
|
|
G |
CASP3 |
caspase 3 |
increases expression multiple interactions |
EXP ISO |
naringin results in increased expression of CASP3 mRNA naringin inhibits the reaction [Dexamethasone results in increased cleavage of CASP3 protein] naringin inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP3 protein]]; [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of CASP3 mRNA]; naringin inhibits the reaction [3-nitropropionic acid results in increased cleavage of CASP3 protein]; naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP3 protein]; naringin inhibits the reaction [Cisplatin results in increased expression of CASP3 mRNA]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of CASP3 mRNA]; rottlerin inhibits the reaction [naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP3 protein]] |
CTD |
PMID:21945202 PMID:22847135 PMID:25773745 PMID:26612654 PMID:28422390 PMID:30130594 PMID:30878453 More...
|
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
CASP9 |
caspase 9 |
increases expression multiple interactions |
EXP ISO |
naringin results in increased expression of CASP9 mRNA [bisphenol A co-treated with naringin] results in decreased expression of CASP9 protein; [NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in decreased expression of CASP9 protein; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of CASP9 protein]; naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP9 protein]; naringin inhibits the reaction [bisphenol A results in increased expression of CASP9 protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of CASP9 protein] |
CTD |
PMID:22847135 PMID:25773745 PMID:32172062 PMID:32428650 PMID:32810514 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; naringin inhibits the reaction [Ferric Compounds results in decreased activity of CAT protein]; naringin inhibits the reaction [Nanotubes, Carbon results in decreased activity of CAT protein] naringin inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]; naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased activity of CAT protein]; naringin inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; naringin inhibits the reaction [Cisplatin results in increased expression of CAT protein]; naringin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; naringin inhibits the reaction [nickel sulfate results in decreased activity of CAT protein] |
CTD |
PMID:20950607 PMID:21345335 PMID:21945202 PMID:22198281 PMID:25773745 PMID:26120027 PMID:26612654 PMID:29658312 PMID:33992719 More...
|
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA]; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein] naringin inhibits the reaction [Cyclophosphamide results in increased expression of CCL2 mRNA] |
CTD |
PMID:22965302 PMID:33992719 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
|
|
G |
CCL3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL3 mRNA]; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein] |
CTD |
PMID:22965302 |
|
NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
|
|
G |
CCL5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CCL5 protein] |
CTD |
PMID:21500970 |
|
NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
|
|
G |
CCND1 |
cyclin D1 |
decreases expression multiple interactions increases expression |
EXP ISO |
naringin results in decreased expression of CCND1 protein naringin inhibits the reaction [Dexamethasone results in increased expression of CCND1 mRNA] naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of CCND1 protein] naringin results in increased expression of CCND1 mRNA |
CTD |
PMID:18296682 PMID:18951945 PMID:24915843 PMID:26482937 PMID:30878453 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCNE1 |
cyclin E1 |
decreases expression |
EXP ISO |
naringin results in decreased expression of CCNE1 protein |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr19:29,811,991...29,824,312
Ensembl chr19:29,811,991...29,824,312
|
|
G |
CDK2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in decreased expression of CDK2 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK2 protein]; naringin promotes the reaction [CDKN1A protein binds to CDK2 protein]; naringin results in decreased expression of and results in decreased activity of CDK2 protein; RAF1 protein affects the reaction [naringin results in decreased expression of CDK2 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of CDK2 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK2 protein]; naringin results in decreased expression of and results in decreased activity of CDK2 protein |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789
|
|
G |
CDK4 |
cyclin dependent kinase 4 |
multiple interactions |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of CDK4 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK4 protein]; naringin promotes the reaction [CDKN1A protein binds to CDK4 protein]; naringin results in decreased expression of and results in decreased activity of CDK4 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in decreased expression of CDK4 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK4 protein]; naringin promotes the reaction [CDKN1A protein binds to CDK4 protein]; naringin results in decreased expression of and results in decreased activity of CDK4 protein; RAF1 protein affects the reaction [naringin results in decreased expression of CDK4 protein] |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr12:57,747,727...57,752,310
Ensembl chr12:57,747,727...57,756,013
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
multiple interactions increases expression |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of CDKN1A protein]; HRAS protein affects the reaction [naringin results in increased expression of CDKN1A protein]; naringin promotes the reaction [CDKN1A protein binds to CDK4 protein]; RAF1 protein affects the reaction [naringin results in increased expression of CDKN1A protein] naringin results in increased expression of CDKN1A mRNA; naringin results in increased expression of CDKN1A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of CDKN1A protein]; HRAS protein affects the reaction [naringin results in increased expression of CDKN1A protein]; naringin promotes the reaction [CDKN1A protein binds to CDK2 protein]; naringin promotes the reaction [CDKN1A protein binds to CDK4 protein]; RAF1 protein affects the reaction [naringin results in increased expression of CDKN1A protein] |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
|
|
G |
CFTR |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of CFTR mRNA]; naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of CFTR protein] |
CTD |
PMID:31301536 |
|
NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
naringin results in increased expression of COL1A1 mRNA |
CTD |
PMID:21741227 |
|
NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632
|
|
G |
CPT1A |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
[Dietary Fats co-treated with naringin] results in decreased expression of CPT1A mRNA |
CTD |
PMID:22198281 |
|
NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410
|
|
G |
CSF1R |
colony stimulating factor 1 receptor |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ACP5 mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ATP6V0D2 mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CALCR mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CTSK mRNA] |
CTD |
PMID:21835177 |
|
NCBI chr 5:150,053,295...150,113,365
Ensembl chr 5:150,053,291...150,113,372
|
|
G |
CTNNB1 |
catenin beta 1 |
increases expression multiple interactions |
EXP |
naringin results in increased expression of CTNNB1 mRNA naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of CTNNB1 protein] |
CTD |
PMID:24915843 PMID:26482937 |
|
NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096
|
|
G |
CTSB |
cathepsin B |
multiple interactions |
ISO |
naringin inhibits the reaction [Isoproterenol results in decreased activity of CTSB protein]; naringin inhibits the reaction [Isoproterenol results in increased activity of CTSB protein] |
CTD |
PMID:17188415 |
|
NCBI chr 8:11,842,524...11,868,087
Ensembl chr 8:11,842,524...11,869,533
|
|
G |
CTSD |
cathepsin D |
multiple interactions |
ISO |
naringin inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] |
CTD |
PMID:17188415 |
|
NCBI chr11:1,752,755...1,763,927
Ensembl chr11:1,752,752...1,764,573
|
|
G |
CTSK |
cathepsin K |
multiple interactions decreases expression |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CTSK mRNA] naringin results in decreased expression of CTSK mRNA |
CTD |
PMID:21835177 PMID:24376342 |
|
NCBI chr 1:150,796,208...150,808,260
Ensembl chr 1:150,794,880...150,809,577
|
|
G |
CXCL12 |
C-X-C motif chemokine ligand 12 |
increases expression |
ISO |
naringin results in increased expression of CXCL12 protein |
CTD |
PMID:29510123 |
|
NCBI chr10:44,370,165...44,385,097
Ensembl chr10:44,370,165...44,386,493
|
|
G |
CXCL2 |
C-X-C motif chemokine ligand 2 |
affects expression multiple interactions |
ISO |
naringin affects the expression of CXCL2 mRNA naringin inhibits the reaction [OVAL protein results in increased expression of CXCL2 protein] |
CTD |
PMID:24131540 PMID:25117567 |
|
NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
ISO |
naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CXCL15 mRNA]; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CXCL15 protein] |
CTD |
PMID:22965302 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CXCR4 |
C-X-C motif chemokine receptor 4 |
increases expression |
ISO |
naringin results in increased expression of CXCR4 protein |
CTD |
PMID:29510123 |
|
NCBI chr 2:136,114,349...136,118,149
Ensembl chr 2:136,114,349...136,119,177
|
|
G |
CYBA |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
naringin inhibits the reaction [TNF protein results in increased expression of CYBA mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of CYBA protein] |
CTD |
PMID:25391245 |
|
NCBI chr16:88,643,289...88,651,053
Ensembl chr16:88,643,275...88,651,083
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions |
EXP |
naringin inhibits the reaction [Cadmium Chloride results in increased expression of CYCS protein] |
CTD |
PMID:28422390 |
|
NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
|
|
G |
CYP11B2 |
cytochrome P450 family 11 subfamily B member 2 |
multiple interactions |
EXP |
naringin inhibits the reaction [AGT protein results in increased expression of CYP11B2 mRNA] |
CTD |
PMID:22798349 |
|
NCBI chr 8:142,910,559...142,917,843
Ensembl chr 8:142,910,559...142,917,843
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
decreases activity |
EXP |
naringin results in decreased activity of CYP1A1 protein |
CTD |
PMID:21053930 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
decreases activity |
EXP |
naringin results in decreased activity of CYP1A2 protein |
CTD |
PMID:21053930 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
multiple interactions |
EXP |
naringin binds to and results in decreased activity of CYP1B1 protein |
CTD |
PMID:21053930 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
multiple interactions |
EXP |
naringin inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] |
CTD |
PMID:21053930 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions decreases activity |
EXP |
naringin inhibits the reaction [CYP3A4 protein affects the metabolism of Verapamil] naringin results in decreased activity of CYP3A4 protein |
CTD |
PMID:16013069 PMID:21053930 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
DHFR |
dihydrofolate reductase |
decreases activity |
EXP |
naringin results in decreased activity of DHFR protein |
CTD |
PMID:25418905 |
|
NCBI chr 5:80,626,226...80,654,983
Ensembl chr 5:80,626,226...80,654,983
|
|
G |
DKK1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
EXP |
DKK1 protein inhibits the reaction [naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA]] |
CTD |
PMID:26482937 |
|
NCBI chr10:52,314,281...52,317,657
Ensembl chr10:52,314,281...52,318,042
|
|
G |
EGF |
epidermal growth factor |
multiple interactions |
EXP |
naringin inhibits the reaction [EGF protein affects the localization of RELA protein]; naringin inhibits the reaction [EGF protein results in increased expression of and results in increased phosphorylation of EGFR protein]; naringin inhibits the reaction [EGF protein results in increased expression of MUC5AC mRNA]; naringin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; naringin inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein] |
CTD |
PMID:22766066 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions |
EXP |
naringin inhibits the reaction [EGF protein results in increased expression of and results in increased phosphorylation of EGFR protein] |
CTD |
PMID:22766066 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
ESR1 |
estrogen receptor 1 |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [naringin results in increased expression of ESR1 mRNA] |
CTD |
PMID:23596885 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
ESR2 |
estrogen receptor 2 |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [naringin results in increased expression of ESR2 mRNA] |
CTD |
PMID:23596885 |
|
NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112
|
|
G |
FABP4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased expression of FABP4 mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236
|
|
G |
FADD |
Fas associated via death domain |
increases expression |
EXP |
naringin results in increased expression of FADD mRNA |
CTD |
PMID:22847135 |
|
NCBI chr11:70,203,296...70,207,390
Ensembl chr11:70,203,296...70,207,390
|
|
G |
FAS |
Fas cell surface death receptor |
increases expression |
EXP |
naringin results in increased expression of FAS mRNA |
CTD |
PMID:22847135 |
|
NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605
|
|
G |
FASN |
fatty acid synthase |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the activity of FASN protein]; naringin inhibits the reaction [Dietary Fats results in increased expression of FASN mRNA] |
CTD |
PMID:16427799 PMID:22198281 |
|
NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294
|
|
G |
FGF2 |
fibroblast growth factor 2 |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [naringin results in increased expression of FGF2 mRNA] |
CTD |
PMID:23596885 |
|
NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,708...122,898,236
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin promotes the reaction [FOS protein binds to BMP2 promoter]]; FOS protein affects the reaction [naringin results in increased expression of BMP2 mRNA]; FOS protein affects the reaction [naringin results in increased expression of BMP2 protein]; naringin promotes the reaction [FOS protein binds to BMP2 promoter] naringin results in increased expression of FOS mRNA |
CTD |
PMID:18495116 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
G6PC1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of G6PC mRNA]; naringin inhibits the reaction [Dietary Fats results in increased expression of G6PC mRNA] |
CTD |
PMID:16427799 PMID:22198281 |
|
NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438
|
|
G |
G6PD |
glucose-6-phosphate dehydrogenase |
multiple interactions |
ISO |
naringin inhibits the reaction [nickel sulfate results in decreased activity of G6PD protein] naringin affects the reaction [LEPR protein affects the activity of G6PD protein] |
CTD |
PMID:16427799 PMID:20950607 |
|
NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572
|
|
G |
GAL |
galanin and GMAP prepropeptide |
multiple interactions |
ISO |
naringin inhibits the reaction [Isoproterenol results in increased activity of GAL protein] |
CTD |
PMID:17188415 |
|
NCBI chr11:68,684,544...68,691,175
Ensembl chr11:68,683,779...68,691,175
|
|
G |
GCK |
glucokinase |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of GCK mRNA] |
CTD |
PMID:16427799 |
|
NCBI chr 7:44,143,213...44,189,439
Ensembl chr 7:44,143,213...44,198,170
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of GCLC protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of GCLC protein]; [naringin co-treated with 3-nitropropionic acid] results in increased expression of GCLC mRNA; naringin promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of GCLC protein]; rottlerin inhibits the reaction [naringin results in increased expression of GCLC protein] naringin results in increased expression of GCLC mRNA; naringin results in increased expression of GCLC protein |
CTD |
PMID:22871521 PMID:25773745 |
|
NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
naringin affects the reaction [Cyclophosphamide affects the activity of GPT protein]; naringin inhibits the reaction [sodium arsenite results in increased expression of GPT protein] |
CTD |
PMID:27174133 PMID:33992719 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
GPX1 |
glutathione peroxidase 1 |
increases activity |
ISO |
naringin results in increased activity of GPX1 protein |
CTD |
PMID:23603004 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,176...49,358,353
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
ISO EXP |
naringin inhibits the reaction [3-nitropropionic acid results in decreased activity of GSR protein]; naringin inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein]; naringin inhibits the reaction [nickel sulfate results in decreased activity of GSR protein] naringin inhibits the reaction [Mercuric Chloride results in decreased activity of GSR protein] |
CTD |
PMID:20950607 PMID:21945202 PMID:23650045 PMID:33992719 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
GSTP1 |
glutathione S-transferase pi 1 |
increases expression multiple interactions |
ISO |
naringin results in increased expression of GSTP1 mRNA [naringin co-treated with 3-nitropropionic acid] results in increased expression of GSTP1 mRNA |
CTD |
PMID:22871521 |
|
NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
|
|
G |
GUSB |
glucuronidase beta |
multiple interactions |
ISO |
naringin inhibits the reaction [Isoproterenol results in decreased activity of GUSB protein]; naringin inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:17188415 |
|
NCBI chr 7:65,960,684...65,982,213
Ensembl chr 7:65,960,684...65,982,215
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
naringin inhibits the reaction [Isoproterenol results in increased activity of HMGCR protein] naringin affects the reaction [LEPR protein affects the activity of HMGCR protein] |
CTD |
PMID:16427799 PMID:16906524 |
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions increases expression increases activity |
ISO |
naringin inhibits the reaction [Paraquat results in decreased expression of HMOX1 mRNA]; naringin inhibits the reaction [Paraquat results in decreased expression of HMOX1 protein] naringin results in increased expression of HMOX1 mRNA; naringin results in increased expression of HMOX1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of HMOX1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of HMOX1 protein]; [naringin co-treated with 3-nitropropionic acid] results in increased expression of HMOX1 mRNA; naringin inhibits the reaction [sodium arsenite results in decreased expression of HMOX1 mRNA]; naringin promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of HMOX1 protein]; rottlerin inhibits the reaction [naringin results in increased expression of HMOX1 protein] naringin results in increased activity of HMOX1 protein |
CTD |
PMID:22871521 PMID:23603004 PMID:25773745 PMID:27174133 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HRAS |
HRas proto-oncogene, GTPase |
multiple interactions increases activity |
EXP ISO |
HRAS protein affects the reaction [naringin results in decreased expression of CDK2 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK4 protein]; HRAS protein affects the reaction [naringin results in increased expression of CDKN1A protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] naringin results in increased activity of HRAS protein |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr11:532,242...535,576
Ensembl chr11:532,242...537,321
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
multiple interactions affects expression |
EXP ISO |
naringin inhibits the reaction [Glucose results in increased expression of ICAM1]; naringin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] naringin inhibits the reaction [OVAL protein results in increased expression of ICAM1 protein] naringin affects the expression of ICAM1 mRNA |
CTD |
PMID:22074828 PMID:24131540 PMID:25117567 PMID:25391245 |
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
IFNA1 |
interferon alpha 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Cyclophosphamide results in increased expression of IFNA1 mRNA] |
CTD |
PMID:33992719 |
|
NCBI chr 9:21,440,439...21,441,316
Ensembl chr 9:21,440,439...21,441,316
|
|
G |
IFNG |
interferon gamma |
multiple interactions affects expression |
EXP ISO |
naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] affects the localization of RELA protein]; naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CCL5 protein] naringin inhibits the reaction [OVAL protein results in decreased expression of IFNG protein] naringin affects the expression of IFNG mRNA |
CTD |
PMID:16945185 PMID:21500970 PMID:24131540 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IGF1 |
insulin like growth factor 1 |
affects expression multiple interactions increases expression |
ISO |
naringin affects the expression of IGF1 mRNA naringin inhibits the reaction [Dexamethasone results in increased expression of IGF1 mRNA] naringin results in increased expression of IGF1 mRNA fulvestrant inhibits the reaction [naringin results in increased expression of IGF1 mRNA] |
CTD |
PMID:23596885 PMID:24880026 PMID:30878453 |
|
NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744
|
|
G |
IL10 |
interleukin 10 |
multiple interactions affects expression |
ISO |
naringin inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of IL10 protein] naringin affects the expression of IL10 protein |
CTD |
PMID:22985397 PMID:25117567 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL1B |
interleukin 1 beta |
affects expression multiple interactions |
ISO EXP |
naringin affects the expression of IL1B mRNA [bisphenol A co-treated with naringin] results in increased expression of IL1B protein; [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of IL1B mRNA]; [NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in increased expression of IL1B protein; [NG-Nitroarginine Methyl Ester co-treated with naringin] results in increased expression of IL1B protein; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of IL1B protein]; naringin inhibits the reaction [bisphenol A results in increased expression of IL1B protein]; naringin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of IL1B protein]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of IL1B mRNA] naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL1B mRNA]; naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL1B protein] naringin inhibits the reaction [OVAL protein results in increased expression of IL1B protein] |
CTD |
PMID:24131540 PMID:24880026 PMID:30130594 PMID:32172062 PMID:32428650 PMID:32810514 PMID:33992719 More...
|
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL1R1 |
interleukin 1 receptor type 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Cyclophosphamide results in increased expression of IL1R1 mRNA] |
CTD |
PMID:33992719 |
|
NCBI chr 2:102,070,390...102,179,874
Ensembl chr 2:102,064,544...102,179,874
|
|
G |
IL2 |
interleukin 2 |
affects expression |
ISO |
naringin affects the expression of IL2 protein |
CTD |
PMID:25117567 |
|
NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725
|
|
G |
IL4 |
interleukin 4 |
affects expression multiple interactions |
ISO |
naringin affects the expression of IL4 protein naringin inhibits the reaction [OVAL protein results in increased expression of IL4 protein] |
CTD |
PMID:24131540 PMID:25117567 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
IL6 |
interleukin 6 |
affects expression decreases expression multiple interactions |
ISO EXP |
naringin affects the expression of IL6 mRNA naringin results in decreased expression of IL6 protein naringin affects the expression of IL6 protein [naringin co-treated with Hesperidin] results in decreased expression of IL6 protein; [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of IL6 mRNA]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of IL6 mRNA]; naringin inhibits the reaction [TNF protein results in increased secretion of IL6 protein] naringin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; naringin inhibits the reaction [OVAL protein results in increased expression of IL6 protein] naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL6 mRNA]; naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL6 protein] |
CTD |
PMID:16137700 PMID:19810018 PMID:21820093 PMID:24131540 PMID:24880026 PMID:25117567 PMID:30130594 More...
|
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
IRS1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in decreased phosphorylation of IRS1 protein] |
CTD |
PMID:22198281 |
|
NCBI chr 2:226,731,312...226,799,820
Ensembl chr 2:226,731,312...226,799,820
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin promotes the reaction [JUN protein binds to BMP2 promoter]]; JUN protein affects the reaction [naringin results in increased expression of BMP2 mRNA]; JUN protein affects the reaction [naringin results in increased expression of BMP2 protein]; naringin promotes the reaction [JUN protein binds to BMP2 promoter] naringin results in increased expression of JUN mRNA |
CTD |
PMID:18495116 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
LCAT |
lecithin-cholesterol acyltransferase |
multiple interactions |
ISO |
naringin inhibits the reaction [Isoproterenol results in decreased activity of LCAT protein] |
CTD |
PMID:16906524 |
|
NCBI chr16:67,939,750...67,944,120
Ensembl chr16:67,939,750...67,944,131
|
|
G |
LDHA |
lactate dehydrogenase A |
multiple interactions |
ISO |
naringin inhibits the reaction [Isoproterenol results in increased expression of LDHA protein] |
CTD |
PMID:17188415 |
|
NCBI chr11:18,394,563...18,408,425
Ensembl chr11:18,394,560...18,408,425
|
|
G |
LDHB |
lactate dehydrogenase B |
multiple interactions |
ISO |
naringin inhibits the reaction [Isoproterenol results in increased expression of LDHB protein] |
CTD |
PMID:17188415 |
|
NCBI chr12:21,635,342...21,657,842
Ensembl chr12:21,635,342...21,757,857
|
|
G |
LEP |
leptin |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased expression of LEP protein] [naringin co-treated with Hesperidin] results in decreased expression of LEP protein; naringin inhibits the reaction [Glucose results in increased expression of LEP protein] |
CTD |
PMID:21820093 PMID:22198281 PMID:24399619 |
|
NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629
|
|
G |
LEPR |
leptin receptor |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the abundance of Glucose]; naringin affects the reaction [LEPR protein affects the activity of FASN protein]; naringin affects the reaction [LEPR protein affects the activity of G6PD protein]; naringin affects the reaction [LEPR protein affects the activity of HMGCR protein]; naringin affects the reaction [LEPR protein affects the expression of G6PC mRNA]; naringin affects the reaction [LEPR protein affects the expression of GCK mRNA]; naringin affects the reaction [LEPR protein affects the expression of PCK1 mRNA]; naringin affects the reaction [LEPR protein affects the expression of PPARG protein]; naringin affects the reaction [LEPR protein affects the expression of SLC2A2 protein]; naringin affects the reaction [LEPR protein affects the expression of SLC2A4 protein] naringin inhibits the reaction [Glucose results in increased expression of LEPR protein] |
CTD |
PMID:16427799 PMID:24399619 |
|
NCBI chr 1:65,420,652...65,641,559
Ensembl chr 1:65,420,652...65,641,559
|
|
G |
LPL |
lipoprotein lipase |
multiple interactions |
ISO |
naringin inhibits the reaction [Isoproterenol results in decreased activity of LPL protein] |
CTD |
PMID:16906524 |
|
NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259
|
|
G |
MAOA |
monoamine oxidase A |
multiple interactions |
ISO |
[NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in increased expression of MAOA protein; naringin inhibits the reaction [[bisphenol A co-treated with NG-Nitroarginine Methyl Ester] results in increased activity of MAOA protein]; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of MAOA protein]; naringin inhibits the reaction [bisphenol A promotes the reaction [NG-Nitroarginine Methyl Ester results in increased activity of MAOA protein]]; naringin inhibits the reaction [bisphenol A results in increased activity of MAOA protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester promotes the reaction [bisphenol A results in increased activity of MAOA protein]]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of MAOA protein] |
CTD |
PMID:32172062 PMID:32428650 PMID:32810514 |
|
NCBI chr X:43,655,006...43,746,817
Ensembl chr X:43,654,907...43,746,817
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein] naringin results in decreased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein] naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:18296682 PMID:18951945 PMID:21835177 PMID:22198281 PMID:22766066 PMID:22965302 PMID:25773745 PMID:26721195 More...
|
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK10 |
mitogen-activated protein kinase 10 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK10 protein] |
CTD |
PMID:22198281 |
|
NCBI chr 4:86,010,405...86,594,074
Ensembl chr 4:85,990,007...86,594,625
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions decreases phosphorylation increases phosphorylation |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein]; naringin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] naringin results in decreased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK3 protein]; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK3 protein]; naringin inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:18296682 PMID:18951945 PMID:21835177 PMID:22198281 PMID:22766066 PMID:22965302 PMID:25773745 PMID:26721195 More...
|
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:22198281 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:22198281 |
|
NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
|
|
G |
MIR126 |
microRNA 126 |
increases expression multiple interactions |
EXP |
naringin results in increased expression of MIR126 mRNA MIR126 mRNA affects the reaction [naringin results in decreased expression of VCAM1 mRNA] |
CTD |
PMID:24975661 |
|
NCBI chr 9:136,670,602...136,670,686
Ensembl chr 9:136,670,602...136,670,686
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
naringin results in decreased expression of and results in decreased activity of MMP2 protein |
CTD |
PMID:26721195 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO EXP |
naringin inhibits the reaction [Paraquat results in increased expression of MMP9 mRNA]; naringin inhibits the reaction [Paraquat results in increased expression of MMP9 protein] naringin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; naringin results in decreased expression of and results in decreased activity of MMP9 protein naringin inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of MMP9 protein]; naringin inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; naringin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MMP9 protein] |
CTD |
PMID:19810018 PMID:22985397 PMID:23603004 PMID:25866363 PMID:26721195 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
naringin inhibits the reaction [Tobacco Smoke Pollution results in increased activity of MPO protein] |
CTD |
PMID:22985397 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
MT3 |
metallothionein 3 |
multiple interactions |
EXP |
naringin inhibits the reaction [Cadmium Chloride results in increased expression of MT3 protein] |
CTD |
PMID:28422390 |
|
NCBI chr16:56,589,528...56,591,085
Ensembl chr16:56,589,074...56,591,088
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
naringin inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein] |
CTD |
PMID:19810018 |
|
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,551
|
|
G |
MUC5AC |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
EXP ISO |
naringin inhibits the reaction [EGF protein results in increased expression of MUC5AC mRNA]; naringin inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein] naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased secretion of MUC5AC protein] |
CTD |
PMID:22766066 PMID:31301536 |
|
NCBI chr11:1,157,953...1,201,138
Ensembl chr11:1,157,953...1,201,138
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin affects the localization of NFE2L2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin affects the localization of NFE2L2 protein]; [naringin co-treated with 3-nitropropionic acid] affects the localization of NFE2L2 protein; naringin inhibits the reaction [sodium arsenite results in decreased expression of NFE2L2 mRNA]; naringin promotes the reaction [[Oxygen deficiency co-treated with Oxygen] affects the localization of NFE2L2 protein]; rottlerin inhibits the reaction [naringin affects the localization of NFE2L2 protein] |
CTD |
PMID:22871521 PMID:25773745 PMID:27174133 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,227,595...177,392,697
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Cisplatin results in increased expression of NFKB1 mRNA] |
CTD |
PMID:26120027 PMID:26612654 |
|
NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,331...102,617,302
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
affects degradation multiple interactions |
ISO |
naringin affects the degradation of NFKBIA protein naringin inhibits the reaction [TNFSF11 protein results in increased degradation of NFKBIA protein] |
CTD |
PMID:21835177 PMID:25117567 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,513...35,404,749
|
|
G |
NOS2 |
nitric oxide synthase 2 |
affects expression multiple interactions |
ISO |
naringin affects the expression of NOS2 mRNA naringin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] naringin inhibits the reaction [3-nitropropionic acid results in increased expression of NOS2 mRNA]; naringin inhibits the reaction [Cisplatin results in increased expression of NOS2 mRNA] |
CTD |
PMID:16137700 PMID:22871521 PMID:25117567 PMID:26612654 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOX4 |
NADPH oxidase 4 |
multiple interactions |
EXP |
naringin inhibits the reaction [TNF protein results in increased expression of NOX4 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of NOX4 protein] |
CTD |
PMID:25391245 |
|
NCBI chr11:89,324,353...89,589,557
Ensembl chr11:89,324,353...89,498,187
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
ISO |
[naringin co-treated with 3-nitropropionic acid] results in increased expression of NQO1 mRNA naringin results in increased expression of NQO1 mRNA |
CTD |
PMID:22871521 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
OGDH |
oxoglutarate dehydrogenase |
multiple interactions |
ISO |
naringin inhibits the reaction [Isoproterenol results in decreased activity of OGDH protein] |
CTD |
PMID:17994577 |
|
NCBI chr 7:44,606,627...44,709,066
Ensembl chr 7:44,606,572...44,709,066
|
|
G |
PCK1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of PCK1 mRNA] |
CTD |
PMID:16427799 |
|
NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121
|
|
G |
PDE5A |
phosphodiesterase 5A |
multiple interactions |
ISO |
naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased activity of PDE5A protein]; naringin inhibits the reaction [bisphenol A promotes the reaction [NG-Nitroarginine Methyl Ester results in increased activity of PDE5A protein]]; naringin inhibits the reaction [bisphenol A results in increased activity of PDE5A protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester promotes the reaction [bisphenol A results in increased activity of PDE5A protein]]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of PDE5A protein] |
CTD |
PMID:32172062 PMID:32428650 PMID:32810514 |
|
NCBI chr 4:119,494,403...119,628,804
Ensembl chr 4:119,494,397...119,628,804
|
|
G |
PIK3CA |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
multiple interactions |
ISO |
naringin inhibits the reaction [Dexamethasone results in increased expression of PIK3CA mRNA] |
CTD |
PMID:30878453 |
|
NCBI chr 3:179,148,126...179,240,093
Ensembl chr 3:179,148,114...179,240,093
|
|
G |
PIK3R1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dexamethasone results in increased expression of PIK3R1 mRNA] |
CTD |
PMID:30878453 |
|
NCBI chr 5:68,215,756...68,301,821
Ensembl chr 5:68,215,756...68,301,821
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in decreased expression of PPARA mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of PPARG protein]; naringin inhibits the reaction [Dietary Fats results in increased expression of PPARG mRNA] [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in decreased expression of PPARG mRNA]; naringin inhibits the reaction [Quinolinic Acid results in decreased expression of PPARG mRNA] |
CTD |
PMID:16427799 PMID:22198281 PMID:30130594 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
naringin inhibits the reaction [Ethanol results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:18793633 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PRKCD |
protein kinase C delta |
increases phosphorylation multiple interactions |
ISO |
naringin results in increased phosphorylation of PRKCD protein rottlerin inhibits the reaction [naringin results in increased phosphorylation of PRKCD protein] |
CTD |
PMID:25773745 |
|
NCBI chr 3:53,161,209...53,192,717
Ensembl chr 3:53,156,009...53,192,717
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
affects expression multiple interactions |
ISO |
naringin affects the expression of PTGS2 mRNA; naringin affects the expression of PTGS2 protein naringin inhibits the reaction [3-nitropropionic acid results in increased expression of PTGS2 mRNA] naringin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; naringin inhibits the reaction [OVAL protein results in increased expression of PTGS2 protein] |
CTD |
PMID:16137700 PMID:22871521 PMID:24131540 PMID:25117567 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
RAF1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions increases activity increases phosphorylation |
EXP ISO |
RAF1 protein affects the reaction [naringin results in increased expression of CDKN1A protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] RAF1 protein affects the reaction [naringin results in decreased expression of CDK2 protein]; RAF1 protein affects the reaction [naringin results in decreased expression of CDK4 protein]; RAF1 protein affects the reaction [naringin results in increased expression of CDKN1A protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] naringin results in increased activity of RAF1 protein naringin results in increased phosphorylation of RAF1 protein |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr 3:12,583,601...12,664,117
Ensembl chr 3:12,582,101...12,664,201
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] affects the localization of RELA protein]; naringin inhibits the reaction [EGF protein affects the localization of RELA protein] naringin affects the expression of and affects the activity of RELA protein; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein] |
CTD |
PMID:21500970 PMID:22766066 PMID:22965302 PMID:25117567 |
|
NCBI chr11:65,653,601...65,662,916
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RPS6KB1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
naringin inhibits the reaction [AICA ribonucleotide results in increased phosphorylation of RPS6KB1 protein]; naringin inhibits the reaction [cyanoginosin LR results in increased phosphorylation of RPS6KB1 protein]; naringin inhibits the reaction [Okadaic Acid results in increased phosphorylation of RPS6KB1 protein]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:15342961 PMID:19810018 |
|
NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
increases expression multiple interactions |
ISO EXP |
naringin results in increased expression of RUNX2 mRNA naringin inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein] DKK1 protein inhibits the reaction [naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA]]; naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA] fulvestrant inhibits the reaction [naringin results in increased expression of RUNX2 mRNA] |
CTD |
PMID:21741227 PMID:23596885 PMID:24915843 PMID:26482937 PMID:30878453 |
|
NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349
|
|
G |
SIRT1 |
sirtuin 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Ethanol results in increased expression of SIRT1 mRNA] |
CTD |
PMID:18793633 |
|
NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390
|
|
G |
SLC2A2 |
solute carrier family 2 member 2 |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of SLC2A2 protein] |
CTD |
PMID:16427799 |
|
NCBI chr 3:170,996,347...171,026,720
Ensembl chr 3:170,996,347...171,026,743
|
|
G |
SLC2A4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of SLC2A4 protein] |
CTD |
PMID:16427799 |
|
NCBI chr17:7,281,718...7,288,257
Ensembl chr17:7,281,718...7,288,257
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
multiple interactions |
EXP |
naringin inhibits the reaction [SLCO1A2 protein alternative form results in increased uptake of estrone sulfate]; naringin inhibits the reaction [SLCO1A2 protein results in increased transport of estrone sulfate]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Quercetin]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Quinine] |
CTD |
PMID:24947867 PMID:25466967 PMID:27504015 |
|
NCBI chr12:21,264,600...21,419,634
Ensembl chr12:21,264,600...21,419,594
|
|
G |
SLCO1B1 |
solute carrier organic anion transporter family member 1B1 |
multiple interactions |
EXP |
naringin inhibits the reaction [SLCO1B1 protein results in increased import of Sulfobromophthalein] |
CTD |
PMID:22394605 |
|
NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
|
|
G |
SLCO1B3 |
solute carrier organic anion transporter family member 1B3 |
multiple interactions |
EXP |
naringin inhibits the reaction [SLCO1B3 protein results in increased import of Sulfobromophthalein]; naringin inhibits the reaction [SLCO1B3 protein results in increased uptake of Hydroxyurea] |
CTD |
PMID:21256917 PMID:22394605 |
|
NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911
|
|
G |
SMAD3 |
SMAD family member 3 |
multiple interactions |
ISO |
naringin inhibits the reaction [sodium arsenite results in increased expression of SMAD3 mRNA] |
CTD |
PMID:27174133 |
|
NCBI chr15:67,065,602...67,195,169
Ensembl chr15:67,063,763...67,195,173
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
naringin inhibits the reaction [Ferric Compounds results in decreased activity of SOD2 protein] |
CTD |
PMID:21345335 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SP7 |
Sp7 transcription factor |
increases expression multiple interactions |
ISO EXP |
naringin results in increased expression of SP7 mRNA naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of SP7 mRNA] fulvestrant inhibits the reaction [naringin results in increased expression of SP7 mRNA] |
CTD |
PMID:23596885 PMID:26482937 |
|
NCBI chr12:53,326,575...53,344,793
Ensembl chr12:53,326,575...53,345,315
|
|
G |
SPN |
sialophorin |
multiple interactions increases expression decreases expression |
ISO |
[bisphenol A co-treated with naringin] results in decreased expression of SPN protein; [NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in decreased expression of SPN protein; [NG-Nitroarginine Methyl Ester co-treated with naringin] results in decreased expression of SPN protein; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of SPN protein]; naringin inhibits the reaction [bisphenol A results in increased expression of SPN protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of SPN protein] naringin results in increased expression of SPN protein naringin results in decreased expression of SPN protein |
CTD |
PMID:32172062 PMID:32428650 |
|
NCBI chr16:29,662,963...29,670,876
Ensembl chr16:29,662,979...29,670,876
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
increases expression increases secretion multiple interactions |
ISO EXP |
naringin results in increased expression of SPP1 mRNA; naringin results in increased expression of SPP1 protein naringin results in increased secretion of SPP1 protein fulvestrant inhibits the reaction [naringin results in increased secretion of SPP1 protein] |
CTD |
PMID:18495116 PMID:23596885 PMID:24915843 |
|
NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
affects expression |
ISO |
naringin affects the expression of STAT3 mRNA; naringin affects the expression of STAT3 protein |
CTD |
PMID:25117567 |
|
NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,540
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions affects expression |
ISO |
naringin inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA] naringin inhibits the reaction [Cyclophosphamide results in increased expression of TGFB1 mRNA]; naringin inhibits the reaction [sodium arsenite results in increased expression of TGFB1 mRNA] naringin affects the expression of TGFB1 mRNA |
CTD |
PMID:23603004 PMID:25117567 PMID:27174133 PMID:33992719 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TIMP1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Paraquat results in increased expression of TIMP1 mRNA]; naringin inhibits the reaction [Paraquat results in increased expression of TIMP1 protein] |
CTD |
PMID:23603004 |
|
NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions affects expression |
ISO EXP |
naringin inhibits the reaction [Dietary Fats results in increased expression of TNF protein]; naringin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; naringin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; naringin inhibits the reaction [Paraquat results in increased expression of TNF mRNA] [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of TNF mRNA]; naringin inhibits the reaction [3-nitropropionic acid results in increased expression of TNF mRNA]; naringin inhibits the reaction [[bisphenol A co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF protein]; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of TNF protein]; naringin inhibits the reaction [bisphenol A results in increased expression of TNF protein]; naringin inhibits the reaction [Cisplatin results in increased expression of TNF mRNA]; naringin inhibits the reaction [Cisplatin results in increased expression of TNF protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of TNF protein]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of TNF mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of MMP9 protein]; naringin inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; naringin inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]; naringin inhibits the reaction [TNF protein results in increased secretion of IL6 protein]; naringin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TNF protein] naringin affects the expression of TNF protein naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF mRNA]; naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF protein]; naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] affects the localization of RELA protein]; naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CCL5 protein]; naringin inhibits the reaction [TNF protein results in increased expression of CYBA mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of CYBA protein]; naringin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; naringin inhibits the reaction [TNF protein results in increased expression of NOX4 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of NOX4 protein]; naringin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] naringin affects the expression of TNF mRNA |
CTD |
PMID:16137700 PMID:19810018 PMID:21500970 PMID:22198281 PMID:22871521 PMID:22985397 PMID:23603004 PMID:24131540 PMID:24880026 PMID:25117567 PMID:25391245 PMID:26120027 PMID:26612654 PMID:30130594 PMID:32172062 PMID:32428650 PMID:32810514 More...
|
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFRSF11A |
TNF receptor superfamily member 11a |
decreases expression |
ISO |
naringin results in decreased expression of TNFRSF11A mRNA |
CTD |
PMID:24376342 |
|
NCBI chr18:62,325,310...62,391,288
Ensembl chr18:62,325,287...62,391,288
|
|
G |
TNFRSF11B |
TNF receptor superfamily member 11b |
multiple interactions |
ISO |
naringin inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]; naringin inhibits the reaction [Dexamethasone results in increased expression of TNFRSF11B protein] |
CTD |
PMID:30878453 |
|
NCBI chr 8:118,923,557...118,951,885
Ensembl chr 8:118,923,557...118,951,885
|
|
G |
TNFSF11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ACP5 mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ATP6V0D2 mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CALCR mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CTSK mRNA]; naringin inhibits the reaction [TNFSF11 protein results in increased degradation of NFKBIA protein]; naringin inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21835177 |
|
NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
|
|
G |
TNNT2 |
troponin T2, cardiac type |
multiple interactions |
ISO |
naringin inhibits the reaction [Isoproterenol results in increased expression of TNNT2 protein] |
CTD |
PMID:17188415 |
|
NCBI chr 1:201,359,014...201,377,680
Ensembl chr 1:201,359,008...201,377,764
|
|
G |
TP53 |
tumor protein p53 |
increases expression decreases expression multiple interactions |
EXP ISO |
naringin results in increased expression of TP53 mRNA naringin results in decreased expression of TP53 protein [bisphenol A co-treated with naringin] results in decreased expression of TP53 protein; [NG-Nitroarginine Methyl Ester co-treated with naringin] results in decreased expression of TP53 protein; naringin inhibits the reaction [[bisphenol A co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TP53 protein]; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of TP53 protein]; naringin inhibits the reaction [bisphenol A results in increased expression of TP53 protein]; naringin inhibits the reaction [Cisplatin results in increased expression of TP53 mRNA]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of TP53 protein] |
CTD |
PMID:22847135 PMID:26120027 PMID:26612654 PMID:32172062 PMID:32428650 PMID:32810514 More...
|
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
|
|
G |
TSLP |
thymic stromal lymphopoietin |
multiple interactions |
EXP ISO |
naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TSLP mRNA]; naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TSLP protein] naringin inhibits the reaction [OVAL protein results in increased expression of TSLP protein] |
CTD |
PMID:24131540 |
|
NCBI chr 5:111,070,062...111,078,026
Ensembl chr 5:111,070,062...111,078,026
|
|
G |
UCP2 |
uncoupling protein 2 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased expression of UCP2 mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr11:73,974,672...73,983,202
Ensembl chr11:73,974,672...73,982,843
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases expression |
EXP |
MIR126 mRNA affects the reaction [naringin results in decreased expression of VCAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] naringin results in decreased expression of VCAM1 mRNA; naringin results in decreased expression of VCAM1 protein |
CTD |
PMID:24975661 PMID:25391245 |
|
NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045
|
|
G |
VEGFC |
vascular endothelial growth factor C |
affects expression |
ISO |
naringin affects the expression of VEGFC mRNA |
CTD |
PMID:24880026 |
|
NCBI chr 4:176,683,538...176,792,922
Ensembl chr 4:176,683,538...176,792,922
|
|
|